false FY 0001517681 P3Y P3Y P3Y P5Y P3Y P3Y 0001517681 2023-07-01 2024-06-30 0001517681 2023-12-29 0001517681 2024-09-25 0001517681 2024-06-30 0001517681 2023-06-30 0001517681 us-gaap:RelatedPartyMember 2024-06-30 0001517681 us-gaap:RelatedPartyMember 2023-06-30 0001517681 us-gaap:NonrelatedPartyMember 2024-06-30 0001517681 us-gaap:NonrelatedPartyMember 2023-06-30 0001517681 PPCB:FormerDirectorMember 2024-06-30 0001517681 PPCB:FormerDirectorMember 2023-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001517681 us-gaap:SeriesBPreferredStockMember 2023-06-30 0001517681 2022-07-01 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-06-30 0001517681 us-gaap:CommonStockMember 2022-06-30 0001517681 PPCB:CommonStockIssuableMember 2022-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001517681 PPCB:SubscriptionReceivableMember 2022-06-30 0001517681 us-gaap:RetainedEarningsMember 2022-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2022-06-30 0001517681 2022-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001517681 us-gaap:CommonStockMember 2023-06-30 0001517681 PPCB:CommonStockIssuableMember 2023-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001517681 PPCB:SubscriptionReceivableMember 2023-06-30 0001517681 us-gaap:RetainedEarningsMember 2023-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-07-01 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-06-30 0001517681 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0001517681 PPCB:CommonStockIssuableMember 2022-07-01 2023-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0001517681 PPCB:SubscriptionReceivableMember 2022-07-01 2023-06-30 0001517681 us-gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2023-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2022-07-01 2023-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-07-01 2024-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-07-01 2024-06-30 0001517681 us-gaap:CommonStockMember 2023-07-01 2024-06-30 0001517681 PPCB:CommonStockIssuableMember 2023-07-01 2024-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-06-30 0001517681 PPCB:SubscriptionReceivableMember 2023-07-01 2024-06-30 0001517681 us-gaap:RetainedEarningsMember 2023-07-01 2024-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2024-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2023-07-01 2024-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-06-30 0001517681 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-06-30 0001517681 us-gaap:CommonStockMember 2024-06-30 0001517681 PPCB:CommonStockIssuableMember 2024-06-30 0001517681 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001517681 PPCB:SubscriptionReceivableMember 2024-06-30 0001517681 us-gaap:RetainedEarningsMember 2024-06-30 0001517681 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001517681 us-gaap:TreasuryStockCommonMember 2024-06-30 0001517681 2023-05-01 2023-05-01 0001517681 2023-08-31 0001517681 srt:WeightedAverageMember 2024-06-30 0001517681 srt:WeightedAverageMember 2023-06-30 0001517681 us-gaap:MachineryAndEquipmentMember 2024-06-30 0001517681 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001517681 us-gaap:EmployeeStockOptionMember 2023-07-01 2024-06-30 0001517681 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0001517681 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001517681 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesAWarrantsMember 2023-07-01 2024-06-30 0001517681 PPCB:SeriesAWarrantsMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesBWarrantsMember 2023-07-01 2024-06-30 0001517681 PPCB:SeriesBWarrantsMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesCWarrantsMember 2023-07-01 2024-06-30 0001517681 PPCB:SeriesCWarrantsMember 2022-07-01 2023-06-30 0001517681 PPCB:UnvestedRestrictedStockMember 2023-07-01 2024-06-30 0001517681 PPCB:UnvestedRestrictedStockMember 2022-07-01 2023-06-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2024-06-30 0001517681 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2023-06-30 0001517681 us-gaap:RelatedPartyMember 2024-05-31 0001517681 PPCB:LetterAgreementMember 2023-07-05 0001517681 PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 2023-07-05 0001517681 us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 2023-07-05 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember PPCB:LetterAgreementMember 2023-07-05 0001517681 PPCB:LetterAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2023-07-01 2024-06-30 0001517681 us-gaap:RelatedPartyMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2022-07-01 2023-06-30 0001517681 PPCB:LoanAgreementMember 2024-06-30 0001517681 PPCB:LetterAgreementMember 2024-06-01 2024-06-30 0001517681 PPCB:LoanAgreementMember 2023-06-30 0001517681 PPCB:CrownBridgePartnersLLCMember 2024-06-30 0001517681 us-gaap:LoansPayableMember 2023-08-15 0001517681 us-gaap:LoansPayableMember 2023-08-15 2023-08-15 0001517681 us-gaap:LoansPayableMember 2023-08-01 2023-08-31 0001517681 us-gaap:LoansPayableMember 2024-06-30 0001517681 us-gaap:LoansPayableMember 2023-07-01 2024-06-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-05-24 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-05-24 2024-05-24 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2024-11-30 2024-11-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2024-12-30 2024-12-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-10 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-10 2024-06-10 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember us-gaap:LoansPayableMember 2024-12-15 2024-12-15 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:ScenarioForecastMember 2025-01-15 2025-01-15 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2023-07-01 2024-06-30 0001517681 PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-30 0001517681 us-gaap:LoansPayableMember PPCB:PromissoryNoteMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember srt:MinimumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember srt:MaximumMember 2019-10-01 2019-10-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:OctoberThreeTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2019-07-01 2020-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-09-16 2020-09-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2020-11-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CrownBridgePartnersLLCMember 2022-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2023-06-30 0001517681 PPCB:CrownBridgeFinancingAgreementMember PPCB:CrownBridgePartnersLLCMember 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-07-11 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulyElevenTwentyTwentyTwoThousandEighthundredDiagonalNoteMember 2022-07-11 2022-07-11 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulySixTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-07-06 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulySixTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-07-06 2023-07-06 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulyNineteenTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-07-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:JulyNineteenTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-07-19 2023-07-19 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:AugustSixteenTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-08-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:AugustSixteenTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-08-16 2023-08-16 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:OctoberTwentyTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-10-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:OctoberTwentyTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-10-20 2023-10-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:NovemberTwentyNineTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember PPCB:NovemberTwentyNineTwentyTwentyThreeThousandEighthundredDiagonalNoteMember 2023-11-29 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:MinimumMember 2023-11-29 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember srt:MaximumMember 2023-11-29 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember 2023-11-29 2023-11-29 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:ThousandEightHundredDiagonalLendingLLCMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-08-15 2022-08-15 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-02-14 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-02-14 2023-02-14 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-12-08 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MinimumMember 2023-12-08 2023-12-08 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember srt:MaximumMember 2023-12-08 2023-12-08 0001517681 PPCB:OneFortyFourCapitalMember 2023-06-30 0001517681 PPCB:OneFortyFourCapitalMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2022-07-01 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:OneFortyFourCapitalMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-08-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-08-11 2022-08-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-09-21 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-09-21 2022-09-21 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-08-23 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-08-23 2023-08-23 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-10-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-10-12 2023-10-12 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember 2024-04-12 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-04-12 2024-04-12 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember srt:MinimumMember PPCB:SecuritiesPurchaseAgreementMember 2024-04-12 2024-04-12 0001517681 PPCB:GSCapitalPartnersLLCMember srt:MaximumMember PPCB:SecuritiesPurchaseAgreementMember 2024-04-12 2024-04-12 0001517681 2024-04-12 2024-04-12 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2023-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:GSCapitalPartnersLLCMember 2022-07-01 2023-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember 2023-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember 2024-06-30 0001517681 PPCB:AugustTenTwoThousandAndSeventeenConsultingAgreementMember PPCB:GSCapitalPartnersLLCMember 2023-07-01 2024-06-30 0001517681 PPCB:GSCapitalPartnersLLCMember 2024-06-30 0001517681 PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember 2022-10-06 0001517681 PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember 2022-10-06 2022-10-06 0001517681 PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:RedRoadHoldingsSecuritiesPurchaseAgreementMember 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2022-11-03 2022-11-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2022-11-03 0001517681 PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2022-11-03 2022-11-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2023-07-31 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2023-07-01 2023-07-31 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-03-05 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MinimumMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MaximumMember 2024-03-05 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-20 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MinimumMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember srt:MaximumMember 2024-06-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:HundredAndFourLLCMember 2024-06-30 0001517681 us-gaap:ConvertibleNotesPayableMember 2024-06-30 0001517681 us-gaap:ConvertibleNotesPayableMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2024-06-30 0001517681 PPCB:ConvertibleNotesOneMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleNotesOneMember 2022-07-01 2023-06-30 0001517681 country:US 2023-07-01 2024-06-30 0001517681 country:US 2022-07-01 2023-06-30 0001517681 PPCB:CaresActMember 2020-03-24 2020-03-27 0001517681 country:US 2024-06-30 0001517681 country:AU PPCB:ExpireInTwoThousandTwentyFourMember 2024-06-30 0001517681 country:AU 2024-06-30 0001517681 country:AU 2023-07-01 2024-06-30 0001517681 country:AU 2022-07-01 2023-06-30 0001517681 2022-05-17 0001517681 2022-05-18 0001517681 2022-09-20 0001517681 2022-09-21 0001517681 us-gaap:SeriesAPreferredStockMember 2024-06-30 0001517681 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001517681 us-gaap:SeriesAPreferredStockMember 2023-06-30 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember srt:MaximumMember 2021-11-28 2021-11-30 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember 2021-11-28 2021-11-30 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember 2021-11-30 0001517681 us-gaap:CommonStockMember 2022-07-12 2022-07-13 0001517681 us-gaap:CommonStockMember 2022-07-13 0001517681 2022-07-12 2022-07-13 0001517681 PPCB:CommonStockPurchaseAgreementMember srt:MaximumMember us-gaap:InvestorMember 2023-07-19 2023-07-20 0001517681 PPCB:CommonStockPurchaseAgreementMember srt:MaximumMember us-gaap:InvestorMember 2023-07-20 0001517681 PPCB:CommonStockPurchaseAgreementMember us-gaap:InvestorMember 2023-07-19 2023-07-20 0001517681 2024-02-20 0001517681 2024-06-11 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember srt:MaximumMember 2022-11-02 2022-11-03 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember 2022-11-02 2022-11-03 0001517681 PPCB:DutchessMember PPCB:CommonStockPurchaseAgreementMember 2022-11-03 2022-11-03 0001517681 PPCB:CommonStockPurchaseAgreementMember PPCB:DutchessMember 2022-11-03 0001517681 us-gaap:ConvertibleDebtMember 2022-07-01 2023-06-30 0001517681 us-gaap:ConvertibleDebtMember 2023-06-30 0001517681 us-gaap:ConvertibleDebtMember 2023-07-12 0001517681 PPCB:FairValueMember 2022-07-01 2023-06-30 0001517681 us-gaap:ConvertibleDebtMember 2023-07-01 2024-06-30 0001517681 us-gaap:ConvertibleDebtMember 2024-06-30 0001517681 PPCB:UnderlyingFinancingAgreementsMember 2024-06-30 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-10-23 2022-10-25 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-10-25 0001517681 us-gaap:CommonStockMember 2022-11-14 2022-11-16 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-11-16 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-11-14 2022-11-16 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-07-01 2023-06-30 0001517681 PPCB:ConsultantServicesMember 2022-07-01 2023-06-30 0001517681 PPCB:ConsultantServicesMember PPCB:ConsultantThreeMember 2023-06-30 0001517681 PPCB:ConsultantServicesMember PPCB:ConsultantThreeMember 2022-07-01 2023-06-30 0001517681 PPCB:ConsultantServicesMember PPCB:ConsultantThreeMember 2023-07-10 2023-07-10 0001517681 PPCB:SeriesBWarrantMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesBWarrantMember 2023-06-30 0001517681 PPCB:SeriesAWarrantsMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesAWarrantsMember us-gaap:CommonStockMember 2023-06-30 0001517681 PPCB:SeriesAWarrantsMember 2023-06-30 0001517681 PPCB:SeriesAWarrantsMember 2023-07-01 2024-06-30 0001517681 PPCB:SeriesAWarrantsMember 2024-06-30 0001517681 PPCB:SeriesAWarrantMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:CoventryEnterprisesLLCSecuritiesPurchaseAgreementMember 2022-11-02 2022-11-03 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2019-05-01 2019-05-31 0001517681 PPCB:SecuritiesPurchaseAgreementMember 2020-04-02 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesCWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:PrefundedWarrantsMember 2020-04-03 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesAWarrantsMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesAWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesAWarrantsMember us-gaap:InvestorMember 2020-03-19 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember us-gaap:InvestorMember 2020-03-19 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember PPCB:HolderMember 2020-03-19 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesBWarrantsMember 2020-03-20 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:SeriesCWarrantsMember us-gaap:InvestorMember 2020-03-20 0001517681 PPCB:SeriesBWarrantsMember 2023-03-08 2023-03-08 0001517681 2023-03-08 2023-03-08 0001517681 us-gaap:WarrantMember 2023-03-08 2023-03-08 0001517681 us-gaap:CommonStockMember 2023-03-08 2023-03-08 0001517681 PPCB:SeriesBWarrantsMember 2023-03-08 2023-03-08 0001517681 PPCB:SeriesBWarrantsMember 2023-03-08 0001517681 us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:WarrantMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-08-16 0001517681 us-gaap:WarrantMember 2022-07-01 2023-06-30 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 2022-08-16 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-08-16 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2022-07-01 2023-06-30 0001517681 us-gaap:WarrantMember srt:AffiliatedEntityMember 2024-06-30 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:AuctusFundLLCMember PPCB:AugustTwoThousandNineteenAuctusNoteMember 2023-07-01 2024-06-30 0001517681 us-gaap:WarrantMember 2024-06-30 0001517681 us-gaap:WarrantMember 2023-07-01 2024-06-30 0001517681 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2024-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember srt:AffiliatedEntityMember 2023-07-01 2024-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2024-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2024-06-30 0001517681 PPCB:SeriesBWarrantsMember 2022-07-01 2023-06-30 0001517681 PPCB:SeriesBWarrantsMember 2023-06-30 0001517681 us-gaap:CommonStockMember PPCB:SeriesBWarrantsMember 2022-07-01 2023-06-30 0001517681 2023-12-13 0001517681 2024-01-31 0001517681 srt:ChiefExecutiveOfficerMember 2019-05-01 2019-05-31 0001517681 PPCB:ChiefScientificOfficerMember 2019-05-01 2019-05-31 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2023-06-30 0001517681 PPCB:UnvestedRestrictedStockUnitsMember 2024-06-30 0001517681 PPCB:UnvestedRestrictedStockUnitsMember 2023-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001517681 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001517681 PPCB:TwoThousandNinteenEquityIncentivePlanMember 2024-06-30 0001517681 PPCB:SeriesAWarrantsMember 2024-06-30 0001517681 PPCB:SeriesBWarrantsMember 2024-06-30 0001517681 PPCB:SeriesCWarrantsMember 2024-06-30 0001517681 PPCB:CommonStockWarrantsWithNoClassDesignationMember 2024-06-30 0001517681 PPCB:From2012ThroughThe2014Member 2023-07-01 2024-06-30 0001517681 us-gaap:RoyaltyAgreementTermsMember 2012-06-01 2012-06-30 0001517681 us-gaap:LicenseAgreementTermsMember 2012-06-01 2012-06-30 0001517681 PPCB:OneYearCollaborationAgreementMember 2018-09-13 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2018-09-13 2018-09-13 0001517681 PPCB:TwoYearCollaborationAgreementMember 2020-10-01 2020-10-01 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentOneMember 2020-11-01 2020-11-30 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentTwoMember 2021-03-01 2021-03-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentThreeMember 2021-12-01 2021-12-31 0001517681 PPCB:TwoYearCollaborationAgreementMember PPCB:InstallmentFourMember 2022-09-01 2022-09-30 0001517681 PPCB:UniversityOfJaenMember 2020-10-01 2020-10-01 0001517681 2020-10-01 2020-10-01 0001517681 PPCB:UniversityOfJaenMember PPCB:ResearchAgreementMember 2022-07-27 2022-07-27 0001517681 PPCB:InstallmentOneMember PPCB:ResearchAgreementMember 2022-08-01 2022-08-31 0001517681 PPCB:InstallmentTwoMember PPCB:ResearchAgreementMember 2022-09-01 2022-09-30 0001517681 PPCB:InstallmentThreeMember PPCB:ResearchAgreementMember 2022-12-01 2022-12-31 0001517681 PPCB:InstallmentFourMember PPCB:ResearchAgreementMember 2023-03-01 2023-03-31 0001517681 PPCB:InstallmentFiveMember PPCB:ResearchAgreementMember 2023-07-01 2023-07-31 0001517681 PPCB:ConsultingAgreementMember 2022-07-01 2022-07-01 0001517681 PPCB:ConsultingAgreementMember 2022-07-01 0001517681 PPCB:ConsultingAgreementMember 2023-06-30 0001517681 us-gaap:CommonStockMember PPCB:ConsultantMember 2022-11-16 2022-11-16 0001517681 PPCB:UnderwritingAgreementMember PPCB:EFHuttonLLCMember 2024-05-04 2024-05-04 0001517681 PPCB:EquityAndEquityLinkedPlacementsMember 2024-05-04 0001517681 PPCB:DebtPlacementsMember 2024-05-04 0001517681 us-gaap:CommonStockMember 2024-05-04 2024-05-04 0001517681 2024-05-04 0001517681 srt:MaximumMember 2024-05-04 0001517681 PPCB:ConsultantMember 2024-05-04 2024-05-04 0001517681 PPCB:ConsultantMember 2024-05-04 0001517681 PPCB:ConsultantMember PPCB:MergerAcquisitionAgreementMember 2024-05-04 0001517681 PPCB:ConsultantMember PPCB:InitialPayableMember 2024-05-04 0001517681 PPCB:ConsultantMember 2024-06-30 0001517681 PPCB:NewThreeYearOperatingLeaseAgreementMember 2022-05-04 0001517681 PPCB:NewThreeYearOperatingLeaseAgreementMember 2022-05-04 2022-05-04 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2022-05-04 0001517681 2022-05-04 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember 2016-05-05 2016-05-05 0001517681 PPCB:NorthHorizonPtyLtdMember PPCB:NathanielszMember 2016-05-05 0001517681 us-gaap:AccountingStandardsUpdate201602Member 2016-05-05 2016-05-05 0001517681 PPCB:ThreeYearOperatingLeaseAgreementMember PPCB:NorthHorizonPtyLtdMember 2022-05-04 2022-05-04 0001517681 PPCB:NorthHorizonPtyLtdMember 2023-07-01 2024-06-30 0001517681 PPCB:NorthHorizonPtyLtdMember 2022-07-01 2023-06-30 0001517681 2023-11-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2015-02-25 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2015-02-25 2015-02-25 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2018-03-16 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2018-03-16 2018-03-16 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MinimumMember 2022-08-01 2022-08-01 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2022-08-01 2022-08-01 0001517681 PPCB:MrsNathanielszMember 2018-02-01 2018-02-01 0001517681 PPCB:JamesNathanielszMember 2016-02-25 2016-02-25 0001517681 PPCB:MrsNathanielszMember 2021-07-01 2022-06-30 0001517681 PPCB:MrsNathanielszMember 2023-07-01 2024-06-30 0001517681 PPCB:MrsNathanielszMember 2022-07-01 2023-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2021-08-12 2021-08-12 0001517681 srt:ChiefExecutiveOfficerMember 2020-07-01 2021-06-30 0001517681 srt:ChiefExecutiveOfficerMember PPCB:MrsNathanielszMember 2020-07-01 2021-06-30 0001517681 PPCB:MrNathanielszMember PPCB:BoardOfDirectorsMember 2022-08-01 2022-08-01 0001517681 2021-07-01 2022-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0001517681 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-06-30 0001517681 2024-01-01 2024-01-31 0001517681 srt:ChiefExecutiveOfficerMember 2023-07-01 2024-06-30 0001517681 PPCB:ServicesAgreementMember PPCB:DrKenyonMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:MrNathanielszMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:InitialNathanielszRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:EmploymentAgreementMember PPCB:AdditionalNathanielszRSUsMember 2022-07-01 2023-06-30 0001517681 PPCB:EmploymentAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:EmploymentAgreementMember PPCB:InitialNathanielszRSUsMember 2022-07-01 2023-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2022-10-26 2022-10-26 0001517681 PPCB:NathanielszEmploymentAgreementMember srt:MaximumMember 2023-07-01 2024-06-30 0001517681 PPCB:NathanielszEmploymentAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:ServicesAgreementMember PPCB:InitialKenyonRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:ServicesAgreementMember PPCB:AdditionalKenyonRSUsMember 2019-05-14 2019-05-14 0001517681 PPCB:ServicesAgreementMember 2023-07-01 2024-06-30 0001517681 PPCB:ServicesAgreementMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderOneMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderTwoMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderThreeMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderFourMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderFiveMember 2022-07-01 2023-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderOneMember 2022-07-01 2023-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderTwoMember 2022-07-01 2023-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderThreeMember 2022-07-01 2023-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderFourMember 2022-07-01 2023-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderFiveMember 2022-07-01 2023-06-30 0001517681 PPCB:LenderOneMember 2023-07-01 2024-06-30 0001517681 PPCB:LenderTwoMember 2023-07-01 2024-06-30 0001517681 PPCB:LenderThreeMember 2023-07-01 2024-06-30 0001517681 PPCB:LenderFourMember 2023-07-01 2024-06-30 0001517681 PPCB:LenderFiveMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderOneMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderTwoMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderThreeMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderFourMember 2023-07-01 2024-06-30 0001517681 PPCB:ConvertibleDebtBenchmarkMember us-gaap:LenderConcentrationRiskMember PPCB:LenderFiveMember 2023-07-01 2024-06-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2023-07-01 2024-06-30 0001517681 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember PPCB:ReceivableMember 2022-07-01 2023-06-30 0001517681 us-gaap:ConvertibleDebtMember 2024-06-30 0001517681 us-gaap:ConvertibleDebtMember 2023-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember PPCB:NewDerivativeInstrumentsMember srt:MinimumMember 2024-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember PPCB:NewDerivativeInstrumentsMember srt:MaximumMember 2024-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember 2023-07-01 2024-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember srt:MinimumMember 2024-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember PPCB:NewDerivativeInstrumentsMember srt:MaximumMember 2024-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2024-06-30 0001517681 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ConvertibleDebtMember 2023-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2023-07-01 2024-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2023-07-01 2024-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2022-07-01 2023-06-30 0001517681 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2022-07-01 2023-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2024-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2024-06-30 0001517681 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2023-06-30 0001517681 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001517681 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001517681 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001517681 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001517681 us-gaap:DerivativeMember 2022-06-30 0001517681 us-gaap:DerivativeMember 2022-07-01 2023-06-30 0001517681 us-gaap:DerivativeMember 2023-06-30 0001517681 us-gaap:DerivativeMember 2023-07-01 2024-06-30 0001517681 us-gaap:DerivativeMember 2024-06-30 0001517681 us-gaap:SubsequentEventMember PPCB:LoanAgreementMember 2024-08-01 0001517681 us-gaap:SubsequentEventMember PPCB:LetterAgreementMember 2024-08-01 0001517681 us-gaap:SubsequentEventMember PPCB:LoanAgreementMember 2024-08-01 2024-08-01 0001517681 us-gaap:SubsequentEventMember PPCB:LoanAgreementMember 2024-08-26 0001517681 us-gaap:SubsequentEventMember PPCB:LetterAgreementMember 2024-08-26 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2024-08-02 0001517681 PPCB:SecuritiesPurchaseAgreementMember PPCB:GSCapitalPartnersLLCMember us-gaap:SubsequentEventMember 2024-08-02 2024-08-02 0001517681 us-gaap:SubsequentEventMember PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember srt:MinimumMember 2024-08-02 2024-08-02 0001517681 us-gaap:SubsequentEventMember PPCB:GSCapitalPartnersLLCMember PPCB:SecuritiesPurchaseAgreementMember srt:MaximumMember 2024-08-02 2024-08-02 0001517681 us-gaap:SubsequentEventMember 2024-07-01 2024-09-19 0001517681 us-gaap:SubsequentEventMember 2024-09-19 0001517681 PPCB:ConsultingAgreementMember us-gaap:SubsequentEventMember 2024-08-12 2024-08-12 0001517681 PPCB:ConsultingAgreementMember us-gaap:SubsequentEventMember 2024-08-12 0001517681 us-gaap:SubsequentEventMember 2024-08-07 2024-08-07 0001517681 PPCB:PreReverseStockSplitMember 2023-07-01 2024-06-30 0001517681 PPCB:PreReverseStockSplitMember 2022-07-01 2023-06-30 0001517681 PPCB:PostReverseStockSplitMember 2023-07-01 2024-06-30 0001517681 PPCB:PostReverseStockSplitMember 2022-07-01 2023-06-30 0001517681 PPCB:ReverseStockSplitOneForTenThousandMember 2023-07-01 2024-06-30 0001517681 PPCB:ReverseStockSplitOneForTenThousandMember 2022-07-01 2023-06-30 0001517681 PPCB:ReverseStockSplitOneForFiftyThousandMember 2023-07-01 2024-06-30 0001517681 PPCB:ReverseStockSplitOneForFiftyThousandMember 2022-07-01 2023-06-30 0001517681 PPCB:ReverseStockSplitOneForOneLakhMember 2023-07-01 2024-06-30 0001517681 PPCB:ReverseStockSplitOneForOneLakhMember 2022-07-01 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:AUD iso4217:EUR PPCB:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2024

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 000-54878

 

PROPANC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   33-0662986
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   identification No.)
     
302, 6 Butler Street, Camberwell, VIC Australia   3124
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code   61 03 9882 0780

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered pursuant to section 12(g) of the Act:

Common Stock, par value $0.001 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transaction period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates was $424,536 computed by reference to the closing price of the registrant’s common stock as quoted on otcmarkets.com maintained by OTC Markets, Inc. on December 29, 2023 (which was $0.012 per share), based on 36,169,023 shares of common stock, par value $0.001 per share (“Common Stock”) outstanding on such date. For purposes of the above statement only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

 

As of September 25, 2024, there were 688,022,017 shares of Common Stock issued and outstanding.

 

Documents Incorporated by Reference: None

 

 

 

 

 

 

PROPANC BIOPHARMA, INC.

 

TABLE OF CONTENTS

 

  Part I  
     
Item 1. Business 3
Item 1A. Risk Factors 23
Item 1B. Unresolved Staff Comments 23
Item 2. Properties 23
Item 3. Legal Proceedings 23
Item 4. Mine Safety Disclosure 23
     
  Part II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 24
Item 6. [Reserved] 25
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 25
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 29
Item 8. Financial Statements and Supplementary Data 30
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 31
Item 9A. Controls and Procedures 31
Item 9B. Other Information 33
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 33
     
  Part III  
     
Item 10. Directors, Executive Officers and Corporate Governance 33
Item 11. Executive Compensation 37
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42
Item 13. Certain Relationships and Related Transactions, and Director Independence 44
Item 14. Principal Accounting Fees and Services 45
     
  Part IV  
     
Item 15. Exhibits and Financial Statement Schedules 46
     
Signatures 52

 

2

 

 

Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “intend,” “continue,” “believe,” “expect,” “plan,” “project,” “forecast,” “anticipate,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. The ultimate correctness of these forward-looking statements is dependent upon a number of known and unknown risks and events and is subject to various uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance or achievements expressed or implied by these statements.

 

The following important factors, among others, could affect our future results and events, causing those results and events to differ materially from those views expressed or implied in our forward-looking statements: our ability to continue as a going concern absent new debt or equity financings; our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets; our ability to control costs; our ability to successfully implement our expansion strategies; our current reliance on substantial debt financing that we currently are unable to repay in cash; our ability to obtain adequate new financing; our ability to successfully develop PRP, our lead product candidate; our ability to successfully develop and market our technologies; our ability to obtain and maintain patent protection; our ability to recruit employees and directors with accounting and finance expertise; our dependence on third parties for services; our dependence on key executives; the impact of government regulations, including U.S. Food and Drug Administration regulations; the impact of any future litigation; the availability of capital; changes in economic, business and competitive conditions; and other risks. Any one or more of such risks and uncertainties could have a material adverse effect on us or the value of our common stock, par value $0.001 per share (the “Common Stock”).

 

All forward-looking statements included in this Form-10-K are made only as of the date of this Annual Report on Form 10-K or as of the date indicated. We do not undertake any obligation to, and may not, publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or which we hereafter become aware of, except as required by law. New risks and uncertainties arise from time to time and we cannot predict these events or how they may affect us. When considering these risks, uncertainties and assumptions, you should keep in mind the cautionary statements contained in this Annual Report on Form 10-K and any documents incorporated herein by reference. You should read this Annual Report on Form 10-K and the documents that we incorporate by reference into this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

 

PART I

 

Item 1. Business

 

General

 

As used in this Annual Report on Form 10-K, references to the “Company,” “Propanc,” “we,” “our,” and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references to our “financial statements” are to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K except as the context otherwise requires.

 

We prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, (“U.S. GAAP”). In this Annual Report on Form 10-K, references to “$” and “dollars” are to United States dollars.

 

3

 

 

Overview

 

We are a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. Our novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

 

Our lead product candidate, PRP, is a variation upon our novel formulation and involves proenzymes, the inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we have conducted successful pre-clinical studies on PRP and also commenced preparation for a clinical study in advanced cancer patients. Subject to us receiving sufficient financing, we plan to begin our Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in 2024. Our plan is to then commence our study preparation process with the contract research organization (“CRO”), analytical lab and trial site(s) selection and to begin our clinical trial application for PRP (“CTA”) compilation in the first calendar quarter of 2025 and complete the CTA compilation and submit the CTA in the first half of the 2025 calendar year. In the second calendar quarter of 2025, we plan to begin the preparation of logistics and trial site initiation visits. Subject to raising additional sufficient capital, we subsequently plan to commence a First-In-Human (“FIH”), Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in the second half of the 2025 calendar year, which study we hope to complete within twelve months thereafter. We intend to develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.

 

PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP produces multiple effects on cancerous cells intended to inhibit tumor growth and potentially stop a tumor from spreading through the body.

 

We received notification from the U.S. Food and Drug Administration (“FDA”) in June 2017 that PRP had been conferred Orphan Drug Designation for the treatment of pancreatic cancer. This special status is granted when a rare disease or condition is implicated, and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations.

 

We received a Certificate for Advance Overseas Finding from the Board of Innovation and Science Australia to receive an up to a 43.5% “cash back” benefit from overseas research and development (“R&D”) expenses. The finding relates to the planned Phase Ib clinical trial – Multiple Ascending Dose Studies of proteolytic proenzymes for the treatment of advanced cancer patients suffering from solid tumors planned to be conducted at the Peter MacCallum Cancer Centre, Melbourne, Australia. Overseas activities to be undertaken include the development of an analytical assay for the quantification of active pharmaceutical ingredients (“API”) in PRP and its manufacture of the finished product for the Phase Ib clinical trial.

 

Our POP1 joint research and drug discovery program (“POP1 Program”) is designed to produce a backup clinical compound to PRP. With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, we are undertaking a research project in collaboration with the universities of Jaén and Granada. We entered into a second two-year joint research and collaboration agreement with the University of Jaén, which is undertaking the research activities for the POP1 Program.

 

4

 

 

Our Focus

 

Cancer occurs when cells in the body start to divide quickly and uncontrollably with an ability to migrate from one location and spread to distant sites. A cell becomes cancerous when it becomes undifferentiated. The cell forgets to do its job and invests all its energy to proliferating. Unlike normal cells, cancer cells multiply, but do not differentiate.

 

Common cancer therapies take advantage of the uncontrolled proliferation of the cancer cells and kill these cells by targeting the cell division machinery. These therapies are effective but affect healthy cells as well, particularly those with a high rate of cell turnover, inducing undesirable side effects.

 

Our goal is to stop cancer not by targeting tumor cell death, but inducing cell differentiation. This is known as differentiation therapy. The key focus is to convince the malignant cells to stop proliferating and return to do their work as a specific cell type. Differentiation therapy does not target cell death, so healthy cells within the patient will not be compromised, unlike chemotherapeutic drugs or gamma irradiation.

 

Differentiation therapy induces the cancer cells into the pathway of terminal differentiation and eventual senescence (i.e., a non-proliferative state). Differentiation therapy acts not only against cancer cells, but interestingly can turn cancer stem cells (undifferentiated cells) towards completely differentiated (i.e., normal) cells.

 

There are natural elements within our body that could help us fight against cancer. Enzymes are natural proteins that stimulate and accelerate biological reactions in the body. Particularly, enzymes secreted by the exocrine pancreas that are essential for the digestion of proteins and fats. More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Professor Beard´s hypothesis with encouraging data from patient treatment.

 

We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. PRP is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio.

 

After extensive laboratory research and a limited amount of human data, we have evidence that PRP:

 

  Reduces cancer cell growth via promotion of cell differentiation;
     
  Enhances cell adhesion and may suppress metastasis progression;
     
  Exhibits no observable serious side effects and improves patient survival;
     
  Alters the external microenvironment of malignant tumors, preventing tumors from returning and spreading.

 

PRP

 

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung liver, uterine and skin cancers.

 

Mechanism Of Action

 

Metastasis occurs because a program inside the cell, called the epithelial-mesenchymal transition (“EMT”) is activated, which causes epithelial cancer cells to become invasive and stem cell-like, features which then allow these cancer cells to spread and metastasize. PRP reverses the conversion from an epithelial to a mesenchymal phenotype and, as such, may reduce the metastatic potential of the tumor cells. PRP also promotes the acquisition of a less malignant phenotype, in addition to a decrease in proliferation due to lineage (i.e., direct descent) specific cellular differentiation.

 

Selectivity

 

PRP treatment affects the Transforming Growth Factor Beta (“TGFβ”) pathway, a significant tumor promoter in late-stage cancer by inducing tumor cell migration and stimulating the EMT program. The likely molecular targets are proteinase-activated-receptors (“PAR”) type 1 and 2, which are over frequently overexpressed in many types of cancers. Trypsinogen and chymotrypsinogen are activated by proteases in the extracellular matrix of tumor cells. In turn, trypsin (activated trypsinogen) has a preference to activate PAR-2, whilst Chymotrypsin (activated chymotrypsinogen) mainly activates PAR-1.

 

5

 

 

Effects Against Cancer Stem Cells

 

Cancer stem cells are resistant to standard treatments because they remain dormant for long periods, then migrate to other organs, and trigger explosive tumor growth, causing the patient to relapse. Approximately eighty percent of cancers are from solid tumors and metastasis is the main cause of patient death. Our unique patented approach is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy.

 

PRP is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy. Traditional cancer therapies act on tumor replicating cells, but not cancer stem cells, so they can rebuild the tumor mass and can migrate to start a new tumor in another organ. PRP stops cancer stem cells so that a tumor loses the ability to generate new cells and therefore the tumor disappears with no option to form a metastatic tumor elsewhere.

 

PRP treatment regulates up to four relevant intracellular pathways related to cancer spread and metastasis of cancer stem cells. – the TGFβ, Hippo, Wnt and Notch pathways. It promotes the up-regulation of RAC1b, which avoids the hyper-activation of the p38 pathway induced by the TGFβ pathway, leading to the phosphorylation of yes-associated protein (YAP), which sequesters B-catenin in the cytoplasm, blocking the canonical Wnt pathway and inhibiting the Notch pathway. This cascade of reactions implies the disruption of the cancer stem cell phenotype and the reversal of the malignant epithelial to mesenchymal transition process that leads to tumor invasion.

 

PRP Impairs Niche Formation and Tumor Initiation

 

The proenzyme treatment inhibits the expression of genes related to the cancer stem cell phenotype, changing these malignant cells toward a more differentiated and less dangerous cellular condition. PRP interferes with the signals that the primary tumor sends to other tissues to prepare the pre-metastatic niche. Several assays, in vitro and in vivo studies confirm that PRP exerts an anti-tumor effect and acts selectively against all malignant, or tumor elements without affecting the non-tumor microenvironment and preventing its malignification.

 

In Vivo Efficacy of PRP In Pancreatic and Ovarian Tumors

 

The effect of the pro-enzyme formulation PRP at different doses on tumor weight in orthotopically implanted pancreatic and ovary tumors was evaluated. In the pancreatic tumor model, there was significant (*P < 0.05) reduction in mean tumor weight in animals treated for 26 days with trypsinogen/chymotrypsinogen at 83.3/500 mg/kg (30.2 mg; 85.9% inhibition) compared with control (PBS; 214.8 mg). Furthermore, ovary tumor-bearing mice showed a significant (*P < 0.05) reduction in mean tumor weight in animals treated for 21 days with two different doses of trypsinogen/chymotrypsinogen, 9.1/54 mg/kg and 27.5/165 mg/kg, compared with control (PBS). The mean weight of control group tumors was 2062.2 mg while the treated groups presented a mean tumor weight of 1074.2 mg and 957.3 respectively, ranging in a 50% tumor inhibition (52–46%).

 

Overview Of Clinical Studies

 

The clinical efficacy of a suppository formulation containing bovine pancreatic pro-enzymes trypsinogen and chymotrypsinogen was evaluated in the context of a UK Pharmaceuticals Special Scheme at the Dove Clinic in Hampshire, UK by Dr. Julian Kenyon, the Company’s Chief Scientific Officer, and the results were published by the Company in a peer-reviewed journal, Scientific Reports, on behalf of Dr. Kenyon. Clinical effects were studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel cancer and melanoma) after treatment with a rectal formulation of both pancreatic pro-enzymes. Patients were treated daily with a rectal formulation containing 8.92 mg of each of the two pancreatic pro-enzymes and 1.78 mg α-Amylase (A) per suppository. The study was carried out under a UK “Specials” License at the Dove Clinic, Hampshire, UK for periods up to 14 months.

 

No severe or serious adverse events related to the rectal administration were observed. Patients did not experience any hematological side effects as typically seen with classical chemotherapy regimens. No allergic reactions after rectal administration of suppositories were observed.

 

6

 

 

In order to assess the therapeutic activity of rectal administration, overall survival of patients under treatment was compared to the life expectancy assigned to a patient prior to treatment start. 19 of 46 patients (41.3%) with advanced malignant diseases, most of them suffering from metastases, had a survival time significantly longer than expected; in fact, for the whole set of cancer types, mean survival (9.0 months) was significantly higher than mean life expectation (5.6 months). Although the number of patients per cancer indication is naturally quite low, 3 out of 8 patients with prostate cancer and 5 out of 11 patients with gastrointestinal cancers appear to particularly benefit from the treatment with the proenzyme suppositories.

 

PRP proves to be an in vivo effective and non-toxic anti-tumor treatment, able to inhibit angiogenesis and tumor growth, cancer cell migration and invasiveness. Furthermore, a suppository formulation containing both pancreatic proenzymes increased the life expectancy of advanced cancer patients. Consequently, we believe that PRP could have relevant oncological clinical applications for the treatment of solid tumors like advanced pancreatic adenocarcinoma and advanced epithelial ovarian cancer.

 

Cancer Type  

Life Expectation

(months)

 

Survival **

(months)

Pancreatic carcinoma (n = 4)   2   8
    4   *
    <3   7
    <3   4
Ovarian Cancer (n = 7)   4   11
    6   12
    6   11
    <12   38
    <1   1
    4   *
    3   *
Breast Cancer (n = 6)   6   9
    6   *
    2   *
    12   *
    <12   *
    12   *
Colon Rectal Cancer (n = 5)   6   *
    6   *
    12   *
    6   40
    12   *
Gastric Cancer (n = 2)   2   8
    <3   7
Prostate Cancer (n = 8)   4   *
    1   5
    4   *
    <12   *
    12   14
    12   *
    12   *
    12   *
Non-Hodgkin Lymphoma (n = 1)   2   9
Mesothelioma (n = 1)   3   9
Melanoma (n = 2)   6   *
    <3   4
Neuro-endocrine Tumor (n = 1)   10   24
Bladder (n = 2)   <3   *
    12   *
NSCLS (n = 2)   3   5
    6   *
Bowel (n = 2)   <12   *
    <3   3
Small Cell Carcinoma (n = 1)   <12   *
Renal Cancer (n = 1)   <3   *
Abdomen unknown primary (n = 1)   <12   *

 

An overview of clinical results. Patients who met prognosis of life expectation (*). For the whole set of cancer types, mean survival (9.0 months) was statistically significantly higher than mean life expectation (5.6 months). One way ANOVA (analysis of variance) (α = 0.05, P < 0.05).

 

7

 

 

POP1 Joint Research And Drug Discovery Program

 

The POP1 Program is designed to produce a backup clinical compound to PRP, which is targeting metastatic cancer from solid tumors. According to an Emergen Research report published in January 2022, the global metastatic cancer market is projected to reach $111 billion by 2027.

 

To date, recombinant trypsinogen and chymotrypsinogen have been synthesized and purified in the laboratory. In the case of trypsinogen, the initial success of producing trypsinogen synthetically has advanced to the stage where optimization of protein production is underway. Whereas purification and yield of chymotrypsinogen is currently the focus of research.

 

A synthetic version of trypsinogen and chymotrypsinogen could have additional benefits to the global healthcare system that could further capitalize on the new therapeutic approach to treating cancer that PRP offers to cancer sufferers. For example, both proenzymes synthesized by an in vivo (living organism) system to produce crystalized proteins that could be maintained for long periods without suffering degradation, even in the absence of refrigeration. This will be particularly useful for a longer shelf life as well as global distribution of the drug product, particularly in warmer climates and developing regions where refrigeration may not be available. The program’s joint researchers at the universities of Jaén and Granada are currently collaborating with the Institute of Microbiology and Microbial Biotechnology, at the University of Natural Resources and Life Sciences in Vienna, Austria, and are working towards full scale manufacture of a synthetic recombinant formulation to PRP.

 

PRP Target Indications

 

The management of cancer differs widely, with a multitude of factors impacting the choice of treatment strategy. Some of those factors include:

 

  the type of tumor, usually defined by the tissue in the body from which it originated;
     
  the extent to which it has spread beyond its original location;
     
  the availability of treatments, driven by multiple factors including cost, drugs approved, local availability of suitable facilities, etc.;
     
  regional and geographic differences;
     
  whether the primary tumor is amenable to surgery, either as a potentially curative procedure, or as a palliative one; and
     
  the balance between potential risks and potential benefits from the various treatments and, probably most importantly, the patient’s wishes.

 

For many patients with solid cancers, such as breast, ovarian, colorectal, lung and pancreatic cancer, surgery is frequently the first treatment option, often followed by first-line chemotherapy with or without radiotherapy. While the hope is that such procedures are curative, in many instances the tumor returns, and second-line treatment strategies are chosen in an effort to achieve a degree of control over the tumor. In most instances, the benefit is temporary, and eventually the point is reached where the patient’s tumor either fails to respond to treatment adequately, or the treatment has unacceptable toxicity that severely limits its usefulness.

 

8

 

 

Should the planned Phase I, II and III clinical trials confirm the efficacy of PRP, along with the favorable safety and tolerability profile suggested by pre-clinical studies conducted to date, we believe our product will have utility in a number of clinical situations including:

 

  1. In the early-stage management of solid tumors, most likely as part of a multi-pronged treatment strategy in combination with existing therapeutic interventions;
     
  2. As a product that can be administered long term for patients following standard treatment approaches, such as surgery, or chemotherapy, in order to prevent or delay recurrence; and
     
  3. As a preventative measure for patients at risk of developing cancer based on genetic screening.

 

In the near-term and as part of our planned Phase I, II and III clinical trials, we plan to target patients with solid tumors, most likely ovarian and pancreatic, for whom other treatment options have been exhausted. This is a common approach by which most new drugs for cancer are initially tested. Once efficacy and safety have been demonstrated in this patient population, exploration of the potential utility of the drug in earlier stage disease can be undertaken, together with investigation of the drug’s utility in other types of cancers, such as gastro-esophageal tumors, colon or rectal carcinoma might be conducted. A Phase II study in a back-up indication, such as advanced therapy refractant prostate cancer, will also be considered. This indication is based on positive preclinical pharmacology studies.

 

Pancreatic Cancer

 

Pancreatic cancer is one of the most lethal malignancies with a median survival of less than six months and a five-year survival rate of less than 5%. The lethal nature of this disease stems from its propensity rapidly to disseminate to the lymphatic system and distant organs. This aggressive biology and resistance to conventional and targeted therapeutic agents leads to a typical clinical presentation of incurable disease at the time of diagnosis.

 

Pancreatic cancer has claimed notoriety over the last decades by proving to be one of the most recalcitrant solid tumors. As an indicator of its lethality, pancreatic cancer accounts for less than 3% of new cancers diagnosed annually in developed countries; yet, it is the third leading cause of cancer related mortality.

 

Since pancreatic cancer is an essentially fatal condition, disease duration is roughly equivalent with survival time. The median time of survival of patients with pancreatic cancer depends on the extend of disease at the time of diagnosis and ranges from 11 to 20 months for patients who qualified for surgical resection (Stage I/II), to 6-11 months for patients with locally advanced disease (Stage III), and only two to six months for patients with metastatic disease (Stage IV) (Amikura 1995, Richter 2003). Taking these low survival times into consideration, the yearly incidence rates for pancreatic cancer are considered the more relevant measure for this disease.

 

Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data are collected by the National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), and the North American Association of Central Cancer Registries (NAACCR). In 2020, it was estimated that a total of more than 1,806,590 new cancer cases and more than 606,520 cancer deaths occurred in the United States according to the National Cancer Institute. Amongst these, a total of almost 50,000 new cases of pancreatic cancer (3.2% of new cancer cases) were estimated, which resulted in more than 40,000 deaths (8.2% of cancer deaths). This means only 20% survival rate of patients diagnosed with pancreatic cancer.

 

Ovarian Cancer

 

Ovarian cancer is a generic term that can be used for any cancer involving the ovaries, arising from one of the several different cell types of ovaries, including germ cells, specialized gonadal stromal cells and epithelial cells. Epithelial ovarian cancer accounts for approximately 90% of ovarian cancers and is responsible for most ovarian cancer related deaths. Furthermore, several subtypes of ovarian cancer have been described according to different risk factors, different genetic mutations, different biological behaviors and different prognoses. This heterogeneity of the disease has impeded progress in the prevention, early detection, treatment and management of ovarian cancer.

 

9

 

 

In 2020, ovarian cancer is the eighth most diagnosed cancer among women in the world and accounts for an estimated 313,959 new cases and 207,252 deaths worldwide (World Cancer Research Fund International)., In the USA, 19,880 new cases (2015 – 2019) and 12,810 related deaths (2016 – 2020) are estimated to occur (National Cancer Institute). The disease typically presents at late stage when the five-year relative survival rate is only 29%. Few cases (15%) are diagnosed with localized tumor (stage 1), when the five-year survival rate is 92%. Strikingly, the overall five-year relative survival rate generally ranges between 30% to 40% across the globe and has seen only very modest increases since 1995.

 

Current Therapies

 

We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors, which is cancer that originates in organs or tissues other than bone marrow or the lymph system. Common cancer types classified as solid tumors include lung, colorectal, ovarian cancer, pancreatic cancer and liver cancers. In each of these indications, there is a large market opportunity to capitalize on the limitations of current therapies.

 

Current therapeutic options for the treatment of cancer offer, at most, a few months of extra life or tumor stabilization. Some experts believe that drugs that kill most tumor cells do not affect cancer stem cells, which can regenerate the tumor (e.g., chemotherapy). Studies are revealing the genetic changes in cells that cause cancer and spur its growth. This research is providing scientific researchers with many potential targets for drugs. Tumor cells, however, can develop resistance to drugs.

 

Limitations of Current Therapies

 

PRP was developed because of the limitation of current cancer therapies. While surgery is often safe and effective for early-stage cancer, many standard therapies for late-stage cancer urgently need improvement; current treatments generally provide modest benefits, and frequently cause significant adverse effects. Our focus is to provide oncologists and their patients with therapies for metastatic cancer which are more effective than current therapies, and which have a substantially reduced side effect profile.

 

While progress has been made within the oncology sector in developing new treatments, the overall cancer death rate has only improved by fifteen percent over the last 30 years. This is attributed to a reduction in smoking and an increase in 5-year survival rates for cancers.

 

Most of these new treatments have some limitations, such as:

 

  1. significant toxic effects;

 

  2. expense; and

 

  3. limited survival benefits.

 

We believe that our treatment will provide a competitive advantage over the following treatments:

 

  Chemotherapeutics: Side effects from chemotherapy can include pain, diarrhea, constipation, mouth sores, hair loss, nausea and vomiting, as well as blood-related side effects, which may include a low cell count of infection fighting white blood cells (neutropenia), low red blood cell count (anemia), and low platelet count (thrombocytopenia). Our goal is to demonstrate that our treatment will be more effective than chemotherapeutic and hormonal therapies with fewer side effects.
     
  Targeted therapies: The most common type is multi-targeted kinase inhibitors (molecules which inhibit a specific class of enzymes called kinases). Common side effects include fatigue, rash, hand-foot reaction, diarrhea, hypertension and dyspnea (shortness of breath). Further, tyrosine kinases inhibited by these drugs appear to develop resistance to inhibitors. While the clinical findings with PRP are early and subject to confirmation in future clinical trials, no evidence has yet been observed of the development of resistance by the cancer to PRP.

 

10

 

 

  Monoclonal antibodies: Development of monoclonal antibodies is often difficult due to safety concerns. Side effects that are most common include skin and gastro-intestinal toxicities. For example, several serious side effects from Avastin, an anti-angiogenic cancer drug, include gastrointestinal perforation and dehiscence (e.g., rupture of the bowel), severe hypertension (often requiring emergency treatment) and nephrotic syndrome (protein leakage into the urine). Antibody therapy can be applied to various cancer types, but can also be limited to certain genetic sub-populations in many instances.
     
  Immunotherapy: There is a long history of attempts to develop therapeutic cancer vaccines to stimulate the body’s own immune system to attack cancer cells. While these products generally do not have the poor safety profile of standard therapeutic approaches, only a small number of them are FDA-approved and available compared to the number of patients diagnosed with cancer. Furthermore, only a relatively small number of the patient population is eligible to receive and subsequently respond to treatment, as defined by preventing tumor growth.

 

PRP Development Strategy

 

Our goal is to foster early-stage clinical development of PRP to bring it to a significant value inflection point, where the commercial attractiveness of the drug in development, together with a greater likelihood of achieving market authorization, may attract potential interest from licensees seeking to acquire new products. Such value inflection points in the context of cancer drugs are typically at the point where formal, controlled clinical trials have demonstrated either “efficacy” or “proof of concept” – typically meaning that there is controlled clinical trial evidence that the drug is effective in the proposed target patient population, has an acceptable safety profile, and is suitable for further development. It is our intention to progress the development of our technology through the completion of our planned Phase IIa clinical trials and then to seek a licensee for further development beyond that point.

 

As part of that commercial strategy, we intend to:

 

  continue research and development to build our existing intellectual property portfolio, and to seek new, patentable discoveries;
     
  seek to ensure all product development is undertaken in a manner that makes its products approvable in the major pharmaceutical markets, including the U.S., Europe, the UK, Australia and Japan;
     
  aggressively pursue the protection of our technology through all means possible, including patents in all major jurisdictions, and potentially trade secrets; and
     
  make strategic acquisitions to acquire new companies that have intellectual property or products that complement our future goals.

 

PRP Development Plan and Milestones

 

We plan to progress PRP using a conventional early-stage clinical development pathway, which entails:

 

  obtaining regulatory and/or ethics approval to conduct a Phase Ib study; and
     
  conducting Phase IIa multiple escalating dose studies to investigate the safety, tolerability, and pharmacokinetics of PRP administered intravenously to patients.

 

Preclinical development of PRP has been completed, including pharmacology and safety toxicology studies, process development activities and bioanalytical method development. The full-scale good manufacturing practice (“GMP”) finished product manufacture of PRP will be completed in preparation for the FIH Phase Ib study. Validation of the bioanalytical method will also be completed prior to lodging our first CTA, which we plan to undertake at the Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia’s largest cancer hospital. We are collaborating with CROs, manufacturing partners and consultants to complete activities prior to preparing the CTA for the Phase Ib study.

 

11

 

 

We have received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by medical oncologists specializing in pancreatic and ovarian cancers, from the University Hospital of Jaén, in Granada, Spain. We believe that the evaluation will most likely be conducted as separate Phase IIa proof of concept, multi-trial center studies for each target indication. The expressions of interest were confirmed after their evaluation of our scientific literature supporting the use of proenzymes in pancreatic and ovarian cancers. The Phase Iia proof of concept studies will be conducted after the Phase Ib dose escalation study investigating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed at the Peter MacCallum Cancer Centre.

 

In Australia, we receive an up to 43.5% “cash-back” benefit in the form of a refund of our qualified research and, development costs and expenses. We received a refund of $196,937 AUD ($129,132) and $192,872 AUD ($129,841) for the years ended June 30, 2024 and 2023, respectively. We are continuing to evaluate all options to conduct our planned clinical trials in the most cost-efficient manner, while striving to minimize dilution to our stockholders.

 

We anticipate reaching the Phase Iia proof of concept milestone in approximately three to four years, subject to regulatory approval in US, Europe and Australia, and the results from our R&D and licensing activities.

 

Our overhead and expenses are likely to increase from its current level as PRP progresses down the development pathway. This increase will be driven by the need to increase our internal resources in order to effectively manage our research and development activities.

 

Anticipated timeline

 

In second calendar quarter of 2025, we anticipate the submission of the CTA for PRP. We anticipate receiving approval of the CTA in the second half of the 2025 calendar year. Following the CTA, we plan to commence our study preparation process, including CRO Selection and Contracts, Analytical Lab Selection Contracts and Trial Sites Selection and Contracts. In connection with the CTA, this product will be part of our Investigation Medicinal Product Dossier, study protocol and Investigator’s Brochure. In the second half of the 2025 calendar year, we hope to complete the study preparation process together with the Preparation of Logistics and Trial Sites Initiation Visits and complete our CTA review. Commencing in the second half of the 2025 calendar year, we intend to initiate a Phase Ib study in advanced cancer patients with solid tumors and we anticipate costs to be approximately $6.5 million. We will need to raise additional financing to fund our planned Phase I, II and III clinical trials and for working capital.

 

Research Activity   Timeline
CTA   November 2024 – April 2025
Investigational Medicinal Product Dossier    
Phase Ib Clinical Study Protocol    
Investigator’s Brochure    
CTA Compilation   March 2025 – June 2025
CTA Submission   June 2025
CTA Approval   July 2025
CTA Review   July 2025 – August 2025
Contract Research Organization and Contracts   February 2024 – June 2025
Analytical Laboratory Selection and Contracts    
Trial Site Selection and Contracts    
Preparation of Logistics   June 2025 – September 2025
Trial Site Initiation Visits    
First Patient/First Visit   October 2025

 

12

 

 

Pop1 Joint Research And Drug Discovery Program

 

The POP1 Program has been established with our collaborators at the universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells as a consequence of being exposed to our proenzyme formulation. The objective of this work is to understand at the molecular level the targets of our proenzyme formulation, thereby providing the opportunity for new, patentable drugs which can be developed further. We plan to commence a targeted drug discovery program utilizing the identified molecular target to search for novel anticancer agents.

 

The POP1 Program has produced synthetic recombinant versions of the two proenzymes, trypsinogen and chymotrypsinogen. Our joint scientific researchers are developing a novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, the anticancer effects of the synthetic versions will be tested against the naturally derived proenzymes from bovine origin.

 

Financial Objectives

 

Multiple factors, many of which are outside of our control, can impact our ability to achieve our target objectives within the planned time and budgetary constraints. Subject to these caveats, our objective is to complete our planned Phase IIa study for PRP within the proposed timeline.

 

We primarily outsource services, skills and expertise to third parties as required to achieve our scientific and corporate objectives. As the business grows and gains more personnel, outsourcing will continue to be the preferred model, where fixed and variable costs are carefully managed on a project-by-project basis. This means our R&D activities are carried out by third parties. Additional third parties with specific expertise in research, compound screening and manufacturing (including raw material suppliers) have been contracted as required.

 

Corporate Strategy

 

Our initial focus is to organize, coordinate and finance the various parts of our drug development pipeline. We intend to carefully introduce new personnel into our Company over time as our R&D activities expand. We plan for such personnel to have specific expertise in product development, manufacture and formulation, regulatory affairs, toxicology, clinical operations and business development (including intellectual property management, licensing and other corporate activities). Additional clinical management and development expertise will likely be required at the outset to assist with the development of PRP. Therefore, we anticipate hiring additional employees in order to effectively manage our contractors as our development activities progress.

 

This outsourcing strategy is common in the biotechnology sector and is an efficient way to obtain access to the necessary skills required to progress a project, in particular as the required skills change as the project progresses from discovery, through manufacturing and non-clinical development and into clinical trials. We anticipate that we will continue to use this model, thereby retaining the flexibility to contract in the appropriate resource as and when required.

 

We intend to seek and identify potential licensing partners for our product candidates as they progress through the various development stages, reaching certain milestones and value inflection points. If a suitable licensee is identified, a potential licensing deal could consist of payments for certain milestones, plus royalties from future sales if the product is able to receive approval from the relevant regulatory authorities where future product sales are targeted. We intend to seek and identify potential licensees based on the initial efficacy data from Phase II clinical trials. To accomplish this objective, we have commenced discussions with potential partners in our current preclinical phase of development.

 

13

 

 

As part of our overall expansion strategy, from time to time, we investigate potential intellectual property acquisition opportunities to expand our product portfolio. While our initial focus is on the development of PRP as our lead product candidate, other potential product candidates may also be considered for future preclinical and clinical development. These potential opportunities have arisen from other research and development organizations, which either own existing intellectual property or are currently developing new intellectual property, which may be of interest to us. These opportunities are possible new cancer treatments that are potentially less toxic than existing treatment approaches and are able to fill an existing gap in the treatment process, such as a systemic de-bulking method which could reduce the size and threat of metastases to a more manageable level for late-stage cancer patients.

 

We believe these potential treatment approaches will be complementary to existing treatment regimens and PRP. No formal approaches regarding such other products have currently been made and it is unknown whether we will engage in any such discussion in the near future. However, as we further develop PRP within the development pathway, we intend to assess future opportunities that may arise to use the expertise of our management and scientific personnel for future prospective R&D projects.

 

Current Operations

 

We are at a pre-revenue stage. We do not know when, if ever, we will be able to commercialize any of our products and to begin to generate revenue. We are focusing our efforts on organizing, coordinating and financing the various aspects of our drug R&D program described herein. In order to commercialize any of our products, we must complete preclinical development, Phase Ib, IIa and IIb clinical trials in Europe, the U.S., UK, Australia or elsewhere, and satisfy the applicable regulatory authority that PRP is safe and effective. If the results from Phase II trials are convincing, we will seek conditional approval from the applicable regulatory authorities sooner. From the time we commence clinical trials for any product, we estimate it will take approximately three to four years if we seek conditional approval upon completion of Phase II trials. When we advance our development projects sufficiently down the development pathway and achieve a major increase in value, such as obtaining interim efficacy data from Phase II clinical trials, we will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.

 

Market Opportunity

 

The global metastatic cancer treatment market is predicted to reach $111 billion by 2027, according to a January 2022 report by Emergen Research. Demand for new cancer products can largely be attributed to a combination of a rapidly aging population in western countries and changing environmental factors, which together are resulting in rising cancer incidence rates. Worldwide, the World Health Organization estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020. As such, global demand for new cancer treatments which are effective, safe and easy to administer is rapidly increasing. Our treatment will potentially target many aggressive tumor types for which little or few treatment options exist.

 

We plan to target patients with solid tumors, most likely pancreatic and ovarian tumors, for whom other treatment options have been exhausted. Globally these cancers resulted in over 673,255 deaths combined in 2020, according to the World Health Organization. With such a high mortality rate, a substantial unmet medical need exists for new treatments. Once the efficacy and safety of PRP has been demonstrated in late-stage patient populations, we plan to undertake exploration of the utility of the drug in earlier stage disease, together with investigation of the drug’s utility in other types of cancer.

 

14

 

 

Anticipated Market Potential

 

It is difficult to estimate the size of the market opportunity for this specific type of product as a clinically proven, pro-enzyme formulated suppository marketed to oncologists across global territories for specific cancer indications, to the best of management’s knowledge, has not been previously available. However, the markets for potential market for pancreatic and ovarian cancers may be characterized as follows:

 

  The world market for pancreatic cancer drugs is projected to grow to $6.93 billion by the year 2030, according to Brainy Insights. Major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, Roche Holding AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc., among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences, Inc., which is engaged into number of drugs for cancer. developments performed by the companies are helping the market to grow in the coming years.
     
  The global market for ovarian cancer drugs expected to reach $13.9 billion by 2029, according to iHealthcareAnalyst. This will be driven by continued uptake and expected launches of the approved PARP (poly adenosine diphosphate-ribose polymerase) inhibitors. Major competitors operating in the global ovarian cancer treatment market include AbbVie Inc., AstraZeneca PLC (Acerta Pharma), Boehringer Ingelheim International GmbH, Chugai Pharmaceutical Co., Ltd., GSK plc (formerly, GlaxoSmithKline plc (Tesaro)), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Oncotelic Therapeutics, Inc. (formerly, Mateon Therapeutics, Inc.), Merck & Co., Inc., Novartis AG, Kazia Therapeutics Limited (formerly, Novogen Limited), Vivesto AB (formerly, Oasmia Pharmaceutical AB), Pfizer Inc., Pharma Mar S.A., and Roche Holding AG.

 

New products can be defined as addition-in-class, advance-in-class, or first-in-class, depending on their degree of innovation. Addition-in-class products, defined as new APIs with established mechanisms of action, are often clinically important and highly commercially successful. Advance-in-class product innovation, defined as significantly differentiated and innovative new APIs, albeit with established mechanisms of action, remains a highly attractive strategy. However, first-in-class innovation, defined as products with a molecular target and/or mechanism of action not found in any approved products globally, remains the key product development strategy in terms of providing the greatest degree of differentiation, extending to a first-mover advantage and potentially the capture of significant market share.

 

Based on the current situation for these two markets, we believe there is an attractive opportunity in both the pancreatic and ovarian cancer market sectors for the introduction of PRP as a first-in-class, clinically proven product which can achieve new benefits for patients in terms of survival and quality of life. The current concentration of products suggests oncologists may be willing to try newly approved products, particularly if they can exhibit a favorable safety profile, although substantive R&D activities will be necessary to both obtain regulatory approval, and to generate the clinical safety and efficacy data needed to convince clinicians to use a new product.

 

License Agreements

 

University of Bath Commercialization Agreement

 

We previously sponsored a collaborative research project at the University of Bath to investigate the cellular and molecular mechanisms underlying the potential clinical approach of our proprietary proenzyme formulation. As a result of this undertaking, we entered into a Commercialization Agreement with the University of Bath, dated November 12, 2009 (the “Commercialization Agreement”), where, initially, we held an exclusive license with the University of Bath, and where we and University of Bath co-owned the intellectual property relating to our proenzyme formulations. The Commercialization Agreement originally provided for University of Bath to assign the Patents (as defined therein) to Propanc in certain specified circumstances, such as successful completion of a clinical trial and commencement of a Phase II (proof of concept) clinical trial.

 

15

 

 

On June 14, 2012, we and the University of Bath agreed to an earlier assignment to us of the patents pursuant to an Assignment and Amendment Deed, on the provision that the University of Bath retains certain rights arising from the Commercialization Agreement, as follows:

 

  The University of Bath reserves for itself (and its employees and students and permitted academic sub-licensees with respect to research use) the non-exclusive, irrevocable, worldwide, royalty free right to use the patents for research use;
     
  The publication rights of the University of Bath specified in the contract relating to the original research made between the parties with an effective date of July 18, 2008 will continue in force;
     
  We agreed to pay to the University of Bath a royalty of two percent of any and all net revenues;
     
  We agreed to use all reasonable endeavors to develop and commercially exploit the patents for the mutual benefit of us and the University of Bath to the maximum extent throughout the covered territory and in any additional territory and to obtain, maintain and/or renew any licenses or authorizations that are necessary to enable such development and commercial exploitation. Without prejudice to the generality of the foregoing, we agreed to comply with all relevant regulatory requirements in respect of our sponsoring and/or performing clinical trials in humans involving the administration of a product or materials within a claim of the patents; and
     
  We agreed to take out with a reputable insurance company and maintain liability insurance coverage prior to the first human trials.

 

In consideration of such assignment, we agreed to pay royalties of two percent of net revenues to the University of Bath. Additionally, we agreed to pay five percent of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement.

 

University of Jaén Collaboration Agreement

 

We have established a collaboration with the University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation. The University of Jaén is providing scientific research activities the Department of Health Sciences, which provides the necessary technical and human resources in order to carry out the programmed works. A Collaboration Agreement (the “Collaboration Agreement”), dated October 1, 2020, was entered into with the main objective for the synthetic development of PRP and its subsequent validation. Pursuant to the Collaboration Agreement, a pre-clinical protocol of safety evaluation was established relating to the antitumor efficacy on cancer stem cells and in orthotopic xenotransplantations derived from cancer stem cells isolated from tumor cell lines, and newly developed synthetic formulation based on the two pancreatic zymogens.

 

The ownership of potential intellectual property rights that may arise as a result of the knowledge obtained through such research project will belong to us. In consideration for payment of the compensation, the University of Jaén assigned and agreed to do all things reasonably required to assign to the contracting entity all industrial property rights arising from such research project.

 

In return for ownership of the industrial property rights arising from such research project, we agreed to pay the University of Jaén two percent of the net sales of any products sold by the contracting entity which fall within the scope of the protection of such industrial property rights.

 

A second collaborative research project commenced on July 27, 2022, with the universities of Jaén and Granada investigating the effect of pancreatic proenzymes against the tumor microenvironment and premetastatic niche. The specific tasks developed under this collaboration focuses on the effects of PRP on cancer associated fibroblasts within the tumor microenvironment. Consistent with existing rights, Propanc will own any intellectual property developed. The personnel of the investigation team of the universities of Jaén and Granada whose work has contributed to the creation of knowledge that give rise to industrial property rights should be listed as inventors. Further, Professor Macarena Perán from the University of Jaén and Professor Marchal from the University of Granada will receive one percent of the net revenue to us from sales of any products sold by us, or on our behalf, which fall within the scope of protection of such industrial property rights. The commencement date for the experiments was September 1, 2022, and the estimated length of time for completion was 24 months.

 

Future Agreements

 

We continue to learn the properties of proenzymes with the long-term aim of screening new compounds for development. We anticipate engaging in future discussions with several technology companies who are progressing new developments in the oncology field as potential additions to our product line. Initially targeting the oncology sector, our focus is to identify and develop novel treatments that are highly effective targeted therapies, with few side effects as a result of toxicity to healthy cells.

 

16

 

 

Intellectual Property

 

The Company has filed multiple patent applications relating to PRP. The Company’s lead patent application has been granted and remains in force in the U.S., Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, the UK, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, the Republic of Korea, India, Brazil and Canada.

 

In 2016 and early 2017, we filed three applications under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT; thus, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016 entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered national phase in October 2018.

 

As of September 25, 2024, we have 84 granted, allowed, or accepted patents and 6 patent applications filed, or under examination in key global jurisdictions, relating to the use of proenzymes against solid tumors, covering PRP.

 

Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer.

 

Regulatory Matters

 

United States

 

Government oversight of the pharmaceutical industry is usually classified into pre-approval and post-approval categories. Most of the therapeutically significant innovative products marketed today are the subject of New Drug Applications (“NDA”). Preapproval activities, based on these detailed applications, are used to assure the product is safe and effective before marketing. In the United States, The Center for Drug Evaluation and Research (“CDER”), is the FDA organization responsible for over-the-counter and prescription drugs, including most biological therapeutics, and generic drugs.

 

Before approval, the FDA may inspect and audit the development facilities, planned production facilities, clinical trials, institutional review boards and laboratory facilities in which the product was tested in animals. After the product is approved and marketed, the FDA uses different mechanisms for assuring that firms adhere to the terms and conditions of approval described in the application and that the product is manufactured in a consistent and controlled manner. This is done by periodic unannounced inspections of production and quality control facilities by FDA’s field investigators and analysts.

 

Federal Food, Drug and Cosmetic Act and Public Health Service Act

 

Prescription drug and biologic products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the testing, manufacturing, safety, efficacy, labelling, storage, record keeping, advertising and promotion of such products under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, and their implementing regulations. The process of obtaining FDA approval and achieving and maintaining compliance with applicable laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply with applicable FDA or other requirements may result in refusal to approve pending applications, a clinical hold, warning letters, civil or criminal penalties, recall or seizure of products, partial or total suspension of production or withdrawal of the product from the market. FDA approval is required before any new drug or biologic, including a new use of a previously approved drug, can be marketed in the United States. All applications for FDA approval must contain, among other things, information relating to safety and efficacy, stability, manufacturing, processing, packaging, labelling and quality control.

 

17

 

 

New Drug Applications (“NDAs”)

 

The FDA’s NDA approval process generally involves:

 

  completion of preclinical laboratory and animal testing in compliance with the FDA’s good laboratory practice, or GLP, regulations;
     
  submission to the FDA of an investigational new drug (“IND”) application for human clinical testing, which must become effective before human clinical trials may begin in the United States;
     
  performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed product for each intended use;
     
  satisfactory completion of an FDA pre-approval inspection of the facility or facilities at which the product is manufactured to assess compliance with the FDA’s “current good manufacturing practice” (“CGMP”) regulations; and
     
  submission to and approval by the FDA of an NDA.

 

The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot guarantee that any approvals for our product candidates will be granted on a timely basis, if at all. Preclinical tests include laboratory evaluation of toxicity and immunogenicity in animals. The results of preclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND application to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Our submission of an IND may not result in FDA authorization to commence clinical trials. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board (“IRB”) covering each medical center proposing to conduct clinical trials must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive “good clinical practice” (“GCP”) regulations, which include requirements that all research subjects provide informed consent and that all clinical studies be conducted under the supervision of one or more qualified investigators.

 

For purposes of an NDA submission and approval, human clinical trials are typically conducted in the following sequential phases, which may overlap:

 

  Phase I: Initially conducted in a limited population to test the product candidate for safety and dose tolerance;
     
  Phase II: Generally conducted in a limited patient population to identify possible adverse effects and safety risks, to determine the initial efficacy of the product for specific targeted indications and to determine optimal dosage. A Phase IIa trial is a non-pivotal, exploratory study that assesses biological activity as its primary endpoint. A Phase IIb trial is designed as a definite dose finding study with efficacy as the primary endpoint. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive Phase III clinical trials;
     
  Phase III: Commonly referred to as pivotal studies. When Phase II evaluations demonstrate that a dose range of the product is effective and has an acceptable safety profile, Phase III clinical trials are undertaken in large patient populations to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically-dispersed clinical trial sites. Generally, replicate evidence of safety and effectiveness needs to be demonstrated in two adequate and well-controlled Phase III clinical trials of a product candidate for a specific indication. These studies are intended to establish the overall risk/benefit ratio of the product and provide adequate basis for product labelling; and
     
  Phase IV: In some cases, the FDA may condition approval of an NDA on the sponsor’s agreement to conduct additional clinical trials to further assess the product’s safety, purity and potency after NDA approval. Such post-approval trials are typically referred to as Phase IV clinical trials.

 

18

 

 

Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. Concurrent with clinical studies, sponsors usually complete additional animal studies and must also develop additional information about the product and finalize a process for manufacturing the product in commercial quantities in accordance with CGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Moreover, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

 

The results of product development, preclinical studies and clinical trials, along with the aforementioned manufacturing information, are submitted to the FDA as part of an NDA. NDAs must also contain extensive manufacturing information. Under the Prescription Drug User Fee Act, the FDA agrees to specific goals for NDA review time through a two-tiered classification system, Standard Review and Priority Review. Standard Review is applied to products that offer at most, only minor improvement over existing marketed therapies. Standard Review NDAs have a goal of being completed within a ten-month timeframe, although a review can take significantly longer. A Priority Review designation is given to products that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A Priority Review takes the FDA six months to review an NDA. It is likely that our product candidates will be granted Standard Reviews. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.

 

The FDA may deny approval of an NDA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or additional pivotal Phase III clinical trials. Even if such data is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials is not always conclusive and the FDA may interpret data differently than we do. Once issued, product approval may be withdrawn by the FDA if ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase IV clinical trials, risk evaluation and mitigation strategies, and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. Products may be marketed only for the approved indications and in accordance with the provisions of the approved label. Further, if there are any modifications to the drug, including changes in indications, labelling or manufacturing processes or facilities, approval of a new or supplemental NDA may be required, which may involve conducting additional preclinical studies and clinical trials.

 

Other U.S. Regulatory Requirements

 

After approval, products are subject to extensive continuing regulation by the FDA, which include company obligations to manufacture products in accordance with GMP, maintain and provide to the FDA updated safety and efficacy information, report adverse experiences with the product, keep certain records, submit periodic reports, obtain FDA approval of certain manufacturing or labeling changes and comply with FDA promotion and advertising requirements and restrictions. Failure to meet these obligations can result in various adverse consequences, both voluntary and FDA-imposed, including product recalls, withdrawal of approval, restrictions on marketing and the imposition of civil fines and criminal penalties. In addition, later discovery of previously unknown safety or efficacy issues may result in restrictions on the product, manufacturer or NDA holder.

 

Propanc, and any manufacturers of our products, are required to comply with applicable FDA manufacturing requirements contained in the FDA’s GMP regulations. GMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. The manufacturing facilities for our products must meet GMP requirements to the satisfaction of the FDA pursuant to a pre-approval inspection before Propanc can use them to manufacture products. Propanc and any third-party manufacturers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.

 

19

 

 

With respect to post-market product advertising and promotion, the FDA imposes complex regulations on entities that advertise and promote pharmaceuticals, which include, among others, standards for direct-to-consumer advertising, promoting products for uses or in patient populations that are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors and civil or criminal penalties. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses.

 

Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing an NDA.

 

Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase IV testing, risk mitigation strategies and surveillance to monitor the effects of an approved product or to place conditions on an approval that could restrict the distribution or use of the product.

 

In June 2017, we were notified by the FDA that PRP had been granted orphan drug designation for the treatment of pancreatic cancer. Orphan drug designation may be granted by the FDA when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations. This qualifies us for various developmental incentives, including protocol assistance, the potential for research grants, the waiver of future application fees, and tax credits for clinical testing if we choose to host future clinical trials in the United States.

 

In October 2017, we submitted a request for a second orphan drug designation for PRP, this time for ovarian cancer.

 

On November 2, 2017, we were notified by the FDA that our request was not granted. The Office of Orphan Products Development (“OOPD”) stated that complete prevalence is used as a measure of disease in ovarian cancer, as this reflects the number of women who have been diagnosed with disease and may be eligible for treatment with the proposed therapy. Therefore, on the date of the submission of our application, the OOPD estimated that the prevalence of ovarian cancer was 228,110 cases. Since the prevalence exceeds the threshold of 200,000 to qualify for orphan drug designation, they could not grant our request. We may consider resubmitting our application if we can identify a suitable sub-population in ovarian cancer, which may meet the target threshold.

 

European Union

 

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials, commercial sales and distribution of our products if we conduct trials for, and market and sell our products, abroad. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or market our product in those countries. The approval process varies from country to country and the time may differ than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Despite these differences, the clinical trials will be conducted according to international standards, such as GCP, GMP and GLP, which is recognized by each foreign country under the International Conference of Harmonization Guidelines. We plan to conduct our trials in each foreign jurisdiction according to these standards, undertaking a FIH Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics, and anti-tumor efficacy of PRP. This will be followed by two Phase II studies evaluating the efficacy and safety of PRP. To ensure harmonization between the jurisdictions, we intend to conduct regulatory meetings in the country in which trials are conducted, as well as with the FDA and the EMA. A pre-IND meeting will be held with the FDA once initial patient data has been collected from the FIH study to ensure acceptability of future planned Phase II trials.

 

Under European Union regulatory systems, we must submit and obtain authorization for a CTA in each member state in which we intend to conduct a clinical trial. After we have completed clinical trials, we must obtain marketing authorization before we can market its product. We must submit applications for marketing authorizations for oncology products under a centralized procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The EMA is the agency responsible for the scientific evaluation of medicines that are to be assessed via the centralized procedure.

 

20

 

 

On June 23, 2016, the UK government held a referendum to gauge voters’ support to remain or leave the European Union. The referendum resulted in 51.9% of UK voters in favor of leaving the European Union, commonly referred to as “Brexit.” On March 29, 2017, the UK invoked Article 50 of Lisbon Treaty to initiate complete withdrawal from the European Union, which was effectuated on January 31, 2020. The center for the EMA was based in London, but the European Union has relocated the center to The Netherlands.

 

Australia

 

In Australia, the relevant regulatory body responsible for the pharmaceutical industry is the Therapeutics Goods Administration (the “TGA”). Prescription medicines are regulated under the Therapeutic Goods Act 1989. Under the Therapeutic Goods Act, the TGA evaluates new products for quality, safety and efficacy before being approved for market authorization, according to similar standards employed by the FDA and EMA in the United States and European Union, respectively. However, receiving market authorization in one or two regions does not guarantee approval in another.

 

Third-Party Payor Coverage and Reimbursement

 

Although none of our product candidates has been commercialized for any indication, if they are approved for marketing, commercial success of our product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state and private levels. In addition, in many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country.

 

Eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies.

 

In many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any foreign market.

 

The regulations that govern marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. In the United States, recently passed legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.

 

Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.

 

21

 

 

Other Regulations

 

We are also subject to numerous federal, state, and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.

 

Competition

 

The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our technology platforms, product candidates, know-how, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. The level of generic competition and the availability of reimbursement from government and other third-party payers will also significantly impact the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

 

Many of our competitors have significantly greater financial resources and expertise in R&D, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

 

Employees

 

As of September 25, 2024, we have one full-time and one part-time employee. In addition to our employees, we engage key consultants and utilize the services of independent contractors to perform various services on our behalf. Some of our executive officers and directors are engaged in outside business activities that we do not believe conflict with our business. Over time, we may be required to hire additional employees or engage independent contractors to execute various projects that are necessary to grow and develop our business. These decisions will be made by our officers and directors, if and when appropriate.

 

Corporate Information

 

Propanc is based in Camberwell, Victoria, Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. PRP is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development.

 

The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company.

 

On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency (the “EMA”) as a small and medium-sized enterprise. As of the date of this prospectus, there has been no activity within this entity.

 

22

 

 

Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better.

 

Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia. Our telephone number is 61 03 9882 0780. Our website is www.propanc.com.

 

Available Information

 

Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents that we will file with or furnish to the SEC will be available free of charge by sending a written request to our Corporate Secretary at our corporate headquarters. Our filings with the SEC are available to the public through the SEC’s website at www.sec.gov.

 

We maintain a corporate website at www.propanc.com. You will be able to access our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports, proxy statements and other information to be filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material will be electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this Annual Report on Form 10-K.

 

ITEM 1A. RISK FACTORS

 

We are not required to provide this information as we are a smaller reporting company.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties.

 

Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia, which we lease from Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our Chief Executive Officer, Chief Financial Officer and a director, and his wife are owners and directors. On May 4, 2022, the Company entered into a three-year lease agreement with North Horizon Pty Ltd. for a monthly rent of $3,000 AUD or $2,176 USD (depending on exchange rate) per month plus taxes.

 

Item 3. Legal Proceedings.

 

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or our subsidiary, threatened against or affecting our Company, our Common Stock, our subsidiary or of our companies or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

IRS Liability

 

As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the accrued expenses and other payable figure in the June 30, 2024 and 2023 consolidated balance sheets. The Company recorded the penalties for all three years during the year ended June 30, 2018. The Company is current on all subsequent filings.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

23

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our Common Stock is quoted under the ticker symbol “PPCB” on the OTC Pink.

 

On September 25, 2024, the last reported sales price per share of our Common Stock on the OTC Pink was $0.0003.

 

Security Holders

 

As of September 25, 2024 we had 81 record holders of our Common Stock.

 

Dividends

 

We have not paid any cash dividends to our stockholders. The declaration of any future cash dividends is at the discretion of our Board and depends upon our earnings, if any, our capital requirements and financial position, and general economic conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

 

Recent Sales of Unregistered Securities

 

Issuance of Shares of Common Stock upon Conversion

 

From April 1, 2024 through June 30, 2024, the Company issued an aggregate of 353,327,677 shares of its common stock at an average contractual conversion price of $0.001 as a result of the conversion of principal of $180,240, interest of $9,608 and conversion fees $1,597 underlying certain outstanding convertible notes converted during such period.

 

Other

 

On April 12, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor purchased a convertible promissory note from the Company in the aggregate principal amount of $27,500, such principal and the interest thereon convertible into shares of Common Stock at the option of the investor at any time.

 

On June 20, 2024, the Company entered into a securities purchase agreement with an investor pursuant to which the investor purchased a convertible promissory note from the Company in the aggregate principal amount of $33,750, such principal and the interest thereon convertible into shares of Common Stock at the option of the investor at any time.

 

Except as otherwise noted, the securities in the transactions described above were sold in reliance on the exemption from registration provided in Section 4(a)(2) of the Securities Act for transactions not involving any public offering. Each of the persons acquiring the foregoing securities was an accredited investor (as defined in Rule 501(a) of Regulation D) and confirmed the foregoing and acknowledged, in writing, that the securities must be acquired and held for investment. All certificates evidencing the shares sold bore a restrictive legend. No underwriter participated in the offer and sale of these securities, and no commission or other remuneration was paid or given directly or indirectly in connection therewith. The proceeds from these sales were used for general corporate purposes.

 

24

 

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our business and results of operations in conjunction with the information set forth in our consolidated financial statements and notes thereto appearing under Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. See “Forward-Looking Statements” on page 3 of this Annual Report on Form 10-K. As used herein, references to the “Company,” “Propanc,” “we,” “our,” and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated.

 

U.S. Dollars are denoted herein by “USD,” “$” and “dollars”.

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information included under “Business,” “Selected Consolidated Financial Data” and our consolidated financial statements and the accompanying notes included elsewhere in this prospectus. The discussion and analysis below are based on comparisons between our historical financial data for different periods and include certain forward-looking statements about our business, operations, and financial performance. These forward-looking statements are subject to risks, uncertainties, assumptions, and other factors described in “Risk Factors.” Our actual results may differ materially from those expressed in, or implied by, those forward-looking statements. See “Special Note Regarding Forward-Looking Statements.”

 

We caution that the foregoing list of factors is not exclusive, and new factors may emerge, or changes to the foregoing factors may occur, that could impact our business. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by the federal securities laws.

 

Certain information contained in this discussion and elsewhere in this prospectus may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and is subject to the safe harbor created by that act. The safe harbor created by the Private Securities Litigation Reform Act will not apply to certain “forward looking statements” because we issued “penny stock” (as defined in Section 3(a)(51) of the Securities Exchange Act of 1934, as amended, and Rule 3(a)(51-1) under the Exchange Act) during the three year period preceding the date(s) on which those forward looking statements were first made, except to the extent otherwise specifically provided by rule, regulation or order of the Securities and Exchange Commission (the “SEC”). We caution readers that certain important factors may affect our actual results and could cause such results to differ materially from any forward-looking statements which may be deemed to have been made in this prospectus or which are otherwise made by or on our behalf. For this purpose, any statements contained in this prospectus that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “explore,” “consider,” “anticipate,” “intend,” “could,” “estimate,” “plan,” or “propose” or the negative variations of those words or comparable terminology are intended to identify forward-looking statements. Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with:

 

  Our ability to raise capital necessary to sustain our anticipated operations and implement our business plan;
  Our ability to implement our business plan;
  Our ability to generate sufficient cash to survive;
  The degree and nature of our competition;
  The lack of diversification of our business plan;
  The general volatility of the capital markets and the establishment of a market for our shares; and
  Disruption in the economic and financial conditions primarily from the impact of past terrorist attacks in the United States, threats of future attacks, police, and military activities overseas and other disruptive worldwide political and economic events and environmental weather conditions.

 

We are also subject to other risks detailed from time to time in our other filings with the SEC and elsewhere in this prospectus. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

We are also subject to other risks detailed from time to time in our other filings with SEC and elsewhere in this prospectus. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

Overview

 

The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware and in January 2011, to reorganize our Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis, whereby Propanc PTY LTD became our wholly-owned subsidiary. Effective April 20, 2017, we changed our name to “Propanc Biopharma, Inc.” to better reflect our current stage of operations and development.

 

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

  

25

 

 

Recent Developments

 

On August 7, 2024, we received written consent in lieu of a meeting by the holders of a majority of the voting power of our outstanding capital stock as of August 7, 2024 and our Board of Directors approving such actions as are necessary for us to proceed to, and accordingly intends to, effectuate and execute a reverse stock split of our issued and outstanding shares of common stock at a ratio somewhere between one post-split share per ten thousand pre-split shares (1:10,000) and one post-split share per one hundred thousand pre-split shares (1:100,000) (the “Reverse Stock Split”). Proportional adjustments for the Reverse Stock Split will be made to our outstanding stock options, warrants and equity incentive plans. We are awaiting the approval of Financial Industry Regulatory Authority (“FINRA”) for the market effectiveness of the Reverse Stock Split.

 

Results of Operations

 

The following discussion should be read in conjunction with the Company’s consolidated financial statements and notes thereto included elsewhere in this Report. The results discussed below are of the Company and its wholly-owned Australian subsidiary, Propanc PTY LTD.

 

Fiscal Year Ended June 30, 2024, as compared to the Fiscal Year Ended June 30, 2023

 

Revenue

 

For the years ended June 30, 2024 and 2023, we generated no revenue because we are currently undertaking research and development activities for market approval and no sales were generated in this period.

 

Administration Expense

 

Administration expense decreased to $1,253,797 for the year ended June 30, 2024 as compared to $1,499,885 for the year ended June 30, 2023. This decrease of approximately $246,000 is primarily attributable to a decrease of approximately $156,000 in general consulting, legal and investor relation fees and decrease in stock-based expenses of approximately $136,000, decrease of approximately $40,000 in employee remuneration expense and decrease in accounting fees of approximately $11,000 offset by increase in marketing expenses of approximately $91,000 and increase in other general and administrative expenses of approximately $5,000.

 

Occupancy Expense

 

Occupancy expenses increased to $34,150 for the year ended June 30, 2024 as compared to $28,841 for the year ended June 30, 2023. This increase of approximately $5,000 is primarily attributable to exchange rate movements over the period when compared to the same period in 2023.

 

Research and Development Expenses

 

Research and development expenses were increased to $248,102 for the year ended June 30, 2024 as compared to $247,919 for the year ended June 30, 2023, an increase in research and development expenses of approximately $180.

 

Such research and development expenses are related to the two-year collaboration agreement with University of Jaén, which was executed in October 2020 to provide certain research services to the Company ending on October 2022, relating to the investigation of a fully synthetic recombinant version of PRP. Additionally, on July 27, 2022, the Company entered into another two-year research agreement with the University of Jaén to provide certain research and experiment services to the Company relating to the investigation of the effects of pancreatic proenzymes against the tumor microenvironment.

 

Interest Expense

 

Interest expense increased to $665,841 for the year ended June 30, 2024, as compared to $532,821 for the year ended June 30, 2023. Interest expense is primarily comprised of approximately $574,000 of debt discount amortization and accretion of put premium and $79,000 of interest expense from accrual of interest expense and other financing fees for the year ended June 30, 2024. This increase in interest expense of approximately $133,000 is primarily attributable to the increase in amortization of debt discount of approximately $91,000 and increase of approximately $47,000 in accretion of put.

 

Derivative Expense

 

Derivative expense were increased to $141,012 for the year ended June 30, 2024 as compared to $0 for the year ended June 30, 2023. This increase is primarily attributable to the issuance of convertible notes in August 2023, October 2023 and April 2024 to GS Capital which initial value was bifurcated from the embedded conversion option and was recorded as derivative expense.

 

Change in Fair Value of Derivative Liabilities

 

Change in fair value of derivative liabilities were increased to a gain of $316,537 for the year ended June 30, 2024 as compared to a loss of $(530,330) for the year ended June 30, 2023. This increase in gain of approximately $847,000 is primarily attributable to the decrease in fair value of the principal amount of convertible notes with bifurcated embedded conversion option derivatives as a result of the decrease in stock prices during the year ended June 30, 2024.

 

26

 

 

Gain from Settlement of accounts payable

 

Gain from settlement of accounts payable was $0 for the year ended June 30, 2024 as compared to $17,499 for the year ended June 30, 2023. On August 16, 2022, the Company and a third-party investor relations consultant agreed to settle an outstanding payable of $23,050 in exchange for 2,305,000 warrants to purchase the Company’s common stock at $0.01 per share with an expiry date of August 16, 2025 and fair market value of $5,551. Accordingly, the Company recognized gain from settlement of accounts payable of $17,499 during the year ended June 30, 2023.

 

Gain on Extinguishment of Debt, net

 

During the year ended June 30, 2024, convertible notes with principal aggregate amount of convertible notes of $130,800, accrued interest of $8,700 and conversion fees of $3,832 containing bifurcated embedded conversion option derivatives were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $352,565, resulting in a loss on extinguishment at the time of conversion of $209,233 and $263,798 of derivative liability fair value was recorded as a gain on extinguishment at the time of conversion, resulting in a net gain of $54,565 which is included in gain on extinguishment of debt in the accompanying consolidated statements of operations.

 

During the year ended June 30, 2023, the principal aggregate amount of convertible notes of $168,200, accrued interest of $16,632 and conversion fees of $1,838 containing bifurcated embedded conversion option derivatives were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $556,272, resulting in a loss on extinguishment at the time of conversion of $369,602 and $352,051 of derivative liability fair value was recorded as a gain on extinguishment at the time of conversion, resulting in a net loss of $17,551 which is included in gain on extinguishment of debt in the accompanying consolidated statements of operations. Additionally, during the year ended June 30, 2023, the Company recognized the remaining put premium of $43,520 related to a convertible note into gain on extinguishment of debt. The holder of such convertible note agreed to surrender all conversion rights in its currently held convertible notes due to violation of Section 15(a)(1) of the Exchange Act, which resulted in a net gain on extinguishment of debt of $25,969 for the year ended June 30, 2023.

 

Foreign Currency Transaction Gain

 

Foreign currency transaction gain increased to a gain of $22,080 for the year ended June 30, 2024 as compared to a gain of $5,885 for the year ended June 30, 2023. This increase of approximately $16,000 is partially attributable to the increase in exchange rates during the year ended June 30, 2024.

 

Net loss

 

Net loss decreased to $1,820,528 for the year ended June 30, 2024 as compared to a net loss of $2,660,566 for the year ended June 30, 2023. The change relates to the factors discussed above.

 

Deemed dividend

 

The Company recognized the value of the effect of a down round feature related to our Series A warrants when triggered. Upon the occurrence of the triggering event that resulted in a reduction of the strike price, the Company measured the value of the effect of the feature as the difference between the fair value of the warrants without the down round feature or before the strike price reduction and the fair value of the warrants with a strike price corresponding to the reduced strike price upon the down round feature being triggered. Accordingly, the Company recognized deemed dividend of $192,960 and $466,273 during the year ended June 30, 2024 and 2023, respectively, with a corresponding reduction of income available to common stockholders upon the alternate cashless exercise of these warrants during the years ended June 30, 2024 and 2023, respectively.

 

Net loss available to common stockholders

 

Net loss available to common stockholders decreased to $2,013,488 for the year ended June 30, 2024 as compared to a net loss available to common stockholders of $3,126,839 for the year ended June 30, 2023. This decrease of approximately $1,067,000 is primarily attributable to the change relates to the factors discussed above.

 

Liquidity and Capital Resources

 

Current Financial Condition

 

As of June 30, 2024, we had total assets of $72,365, comprised primarily of cash of $21,085, GST tax receivable of $2,950, prepaid expenses and other current assets of $1,406, deferred offering cost of $27,117, security deposit of $2,008, and operating lease ROU asset, net of $17,799. As compared to June 30, 2023, we had total assets of $60,328, comprised primarily of cash of $10,047, GST tax receivable of $2,867, prepaid expenses and other current assets of $6,125, property and equipment, net, of $302, operating lease ROU asset, net of $38,988, and security deposit of $1,999.

 

We had current liabilities of $3,792,782, primarily comprised of net convertible debt of $399,325, accounts payable and accrued expenses of $2,100,137, employee benefit liability of $639,371, loans payable of $145,091, loans payable – related party of $71,629, note payable, net of $204,694 and embedded conversion option liabilities of $133,886 as of June 30, 2024. As compared to June 30, 2023, we had current liabilities of $3,158,229, primarily comprised of net convertible debt of $390,539, loans payable of $65,280, accounts payable and accrued expenses of $1,546,425, employee benefit liability of $587,618, and embedded conversion option liabilities of $423,209.

 

We have funded our operations primarily through the issuance of equity and/or convertible securities for cash. The cash was used primarily for payments for research and development, administration expenses, occupancy expenses, professional fees, consultants and travel.

 

During the year ended June 30, 2024 we received proceeds from issuance of note of $190,000, proceeds from issuance of convertible notes of $567,050, proceeds from sale of common stock of $23,057, and total proceeds from issuance of loans payable including from a related party of $304,696.

 

27

 

 

We have substantial capital resource requirements and have incurred significant losses since inception. As of June 30, 2024, we had $21,085 in cash. We depend upon debt and/or equity financing to fund our ongoing operations and to execute our current business plan. Such capital requirements are in excess of what we have in available cash and for which we currently have commitments. Therefore, we presently do not have enough available cash to meet our obligations over the next 12 months. If continued funding and capital resources are unavailable at reasonable terms, we may curtail our plan of operations. We will be required to obtain alternative or additional financing from financial institutions, investors or otherwise, in order to maintain and expand our existing operations. The failure by us to obtain such financing would have a material adverse effect upon our business, financial condition and results of operations, and adversely affecting our ability to complete ongoing activities in connection with our research and development programs.

 

Sources and Uses of Cash

 

 

  

For the years ended

June 30,

 
   2024   2023 
Net cash used in operating activities  $(935,118)  $(1,105,251)
Net cash provided by financing activities  $941,894   $1,113,719 
Effect of exchange rate changes on cash  $4,262   $(2,488)

 

Net Cash Flow from Operating Activities

 

Net cash used in operating activities was $935,118, for the year ended June 30, 2024, due to our net loss of $1,820,528 offset primarily by non-cash charges of amortization of debt discount of $294,005, non-cash interest expense of $3,832, accretion of put premium of $279,711, derivative expense of $141,012, addback change in fair value of derivatives of $316,537, foreign currency transaction gain of $22,080, and gain from extinguishment of debt of $54,565. Net changes in operating assets and liabilities totaled $538,376, which is primarily attributable to increase accrued interest of $78,733, increase in accounts payable of $242,408, and increase in accrued expenses and other payables of $209,962.

 

Net cash used in operating activities was $1,105,251 for the year ended June 30, 2023, due to our net loss of $2,660,566 offset primarily by non-cash charges of amortization of debt discount of $202,952, total stock-based compensation of $141,356, non-cash interest expense of $1,838, accretion of put premium of $232,674, change in fair value of derivatives of $530,330, foreign currency transaction gain of $5,885, and $25,969 gain on extinguishment of debt. Net changes in operating assets and liabilities totaled $472,587, which is primarily attributable to increase in accounts payable of $80,975, increase in accrued expenses and other payables of $130,511, employee benefit liability of $186,912, and accrued interest of $92,474.

 

Net Cash Flow from Financing Activities

 

Net cash provided by financing activities for the year ended June 30, 2024 were $941,894 as compared to $1,113,719 for the year ended June 30, 2023. During the year ended June 30, 2024 we received net proceeds from issuance of convertible notes of $567,050, proceeds from issuance of note of $190,000, total proceeds from issuance of loans including from a related party of $304,696, proceeds from the sale of shares of our common stock of $23,057 offset by repayment of convertible note of $142,909.

 

Net cash provided by financing activities for the year ended June 30, 2023 was $1,113,719. During the year ended June 30, 2023 we received proceeds from the exercise of warrants of $475,000, proceeds from sale of common stock of $24,711, collections of subscription receivables of $23,758 and proceeds from issuance of convertible notes of $590,250.

 

Effect of Exchange Rate

 

The effect of the exchange rate on cash resulted in a $4,262 positive adjustment to cash flows in the year ended June 30, 2024 as compared to a $2,488 negative adjustment to cash flows in the year ended June 30, 2023. The reason for the fluctuation is due to the application of currency translation rates throughout the cash flow statement, the volume of transactions within each period and the daily fluctuation in exchange rates.

 

Critical Accounting Estimates

 

Below is a discussion of our more subjective accounting estimation processes for purposes of explaining (i) the methodology used in calculating the estimates, (ii) the inherent uncertainties pertaining to such estimates, and (iii) the possible effects of a significant variance in actual experience, from that of the estimate, on our financial condition. Estimates involve numerous assumptions that, if incorrect, could create a material adverse impact on the Company’s results of operations and financial condition.

 

Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this filing is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph.

 

28

 

 

Derivative Instruments: ASC 815, “Derivatives and Hedging,” establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion, or payoff, of debt, we record the fair value of the conversion shares, remove the fair value of the related derivative liability, remove any discounts and record a net gain or loss on debt extinguishment.

 

Recent Accounting Pronouncements

 

Please see section captioned “Recent Accounting Pronouncements” in Note 1 to our consolidated financial statements included in this Annual Report for a discussion of recently issued and adopted accounting pronouncements.

 

Going Concern Qualification

 

The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2024, the Company had no revenues, had a net loss of $1,820,528 and had net cash used in operations of $935,118. Additionally, as of June 30, 2024, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $3,767,341, $3,779,059, and $66,698,220, respectively.

 

Our independent registered public accounting firm has included a “Going Concern Qualification” in their audit report for each of the fiscal years ended June 30, 2024 and 2023. In addition, we have negative working capital and convertible debt that is past maturity that we are currently negotiating with lenders in order to amend the maturity dates. The foregoing raises substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. Our ability to continue as a going concern is dependent on our ability to execute our strategy and on our ability to raise additional funds and/or to consummate a public offering. Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity and/or convertible debt financing. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.

 

Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable to smaller reporting companies.

 

29

 

 

Item 8. Financial Statements and Supplementary Data.

 

The following consolidated financial statements of Propanc Biopharma, Inc. are included in this Annual Report on Form 10-K:

 

PROPANC BIOPHARMA, INC.

INDEX TO FINANCIAL STATEMENTS

 

    Page
Consolidated Financial Statements for the Fiscal Years Ended June 30, 2024 and 2023    
     
Report of Independent Registered Public Accounting Firm (PCAOB Firm ID. 106)   F-1
     
Consolidated Balance Sheets as of June 30, 2024 and 2023   F-3
     
Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended June 30, 2024 and 2023   F-4
     
Consolidated Statements of Changes in Stockholders’ Deficit for the years ended June 30, 2024 and 2023   F-5
     
Consolidated Statements of Cash Flows for the years ended June 30, 2024 and 2023   F-6
     
Notes to Consolidated Financial Statements   F-7

 

30

 

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders’ and the Board of Directors of:

Propanc Biopharma, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Propanc Biopharma, Inc. and Subsidiary (the “Company”) as of June 30, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ deficit, and cash flows, for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2024 and 2023 and the consolidated results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has a net loss of $1,820,528 and net cash used in operating activities of $935,118 for the fiscal year ended June 30, 2024. The Company has a working capital deficit, stockholder’s deficit, and accumulated deficit of $3,767,341, $3,779,059, and $66,698,220, respectively, at June 30, 2024. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s Plan regarding these matters is also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

2295 NW Corporate Blvd., Suite 240 ● Boca Raton, FL 33431-7326

Phone: (561) 995-8270 ● Toll Free: (866) CPA-8500 ● Fax: (561) 995-1920

www.salbergco.com • info@salbergco.com

Member National Association of Certified Valuation Analysts ● Registered with the PCAOB

Member CPAConnect with Affiliated Offices Worldwide ● Member AICPA Center for Audit Quality

 

F-1
 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Derivative Liabilities

 

As noted in Footnote 1 “Derivative Instruments” and as described in Footnote 12 “Derivative Financial Instruments and Fair Value Measurements” to the consolidated financial statements, the Company bifurcated embedded conversion features included in convertible debt instruments issued by the Company during the fiscal year that resulted primarily in an initial derivative expense and a gain from the change in fair value of these new and previously recorded derivatives of $141,012 and $316,537, respectively, in fiscal 2024, and derivative liabilities of $133,886 at June 30, 2024.

 

We identified the evaluation of instruments and contracts to determine whether there are embedded derivatives requiring bifurcation from its debt host, the analysis of the accounting treatment and presentation for derivative transactions and the valuation of derivatives as critical audit matters. Auditing management’s analysis of the above critical audit matters was complex and involved a high degree of subjectivity.

 

The primary procedures we performed to address these critical audit matters included (a) Reviewed and tested management’s conclusions as to whether certain instruments or contracts qualified for derivative treatment by comparing management’s analysis and conclusions to authoritative and interpretive literature, (b) Compared the accounting treatment and presentation to that described by the authoritative and interpretive literature, (c) Tested management’s process for valuing derivatives by comparing it to generally accepted methodologies for valuing derivatives, (d) Tested management’s valuation of the derivatives by testing assumptions and data used in the valuation model including the term, volatility and interest rate, and (e) Recomputed the derivative valuations. We agreed with management’s conclusions.

 

/s/ Salberg & Company, P.A.  
   
SALBERG & COMPANY, P.A.  
We have served as the Company’s auditor since 2011  
Boca Raton, Florida  
September 30, 2024  

 

F-2
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

 

   June 30, 2024   June 30, 2023 
         
ASSETS          
           
CURRENT ASSETS:          
Cash  $21,085   $10,047 
GST tax receivable   2,950    2,867 
Prepaid expenses and other current assets   1,406    6,125 
           
TOTAL CURRENT ASSETS   25,441    19,039 
           
Deferred offering costs   27,117    - 
Security deposit - related party   2,008    1,999 
Operating lease right-of-use assets, net - related party   17,799    38,988 
Property and equipment, net   -    302 
           
TOTAL ASSETS  $72,365   $60,328 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable  $1,213,335   $966,718 
Accrued expenses and other payables   792,190    579,707 
Accrued interest   94,612    44,709 
Loans payable   145,091    65,280 
Loans payable - related party   71,629    - 
Note payable, net of discount   204,694    - 
Convertible notes, net of discounts and including put premiums   399,325    390,539 
Operating lease liability - related party, current portion   19,362    21,505 
Embedded conversion option liabilities   133,886    423,209 
Due to former director - related party   29,759    29,630 
Loan from former director - related party   49,528    49,314 
Employee benefit liability   639,371    587,618 
           
TOTAL CURRENT LIABILITIES   3,792,782    3,158,229 
           
NON-CURRENT LIABILITIES:          
Loan payable - long-term - related party, net of discount   58,642    - 
Operating lease liability - long-term portion - related party   -    19,278 
           
TOTAL NON-CURRENT LIABILITIES   58,642    19,278 
           
TOTAL LIABILITIES  $3,851,424   $3,177,507 
           
Commitments and Contingencies (See Note 9)   -    - 
           
STOCKHOLDERS’ DEFICIT:          
Preferred stock, 1,500,005 shares authorized, $0.01 par value:          
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of June 30, 2024 and 2023   -    - 
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 478,802,488 and 6,031,250 shares issued and outstanding as of June 30, 2024 and 2023, respectively   478,802    6,031 
Common stock issuable (0 and 1,621,653 shares as of June 30, 2024 and 2023, respectively)   -    1,621 
Additional paid-in capital   61,217,255    60,311,502 
Accumulated other comprehensive income   1,269,581    1,294,876 
Accumulated deficit   (66,698,220)   (64,684,732)
Treasury stock ($0.001 share)   (46,477)   (46,477)
           
TOTAL STOCKHOLDERS’ DEFICIT   (3,779,059)   (3,117,179)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $72,365   $60,328 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

 

   2024   2023 
   For the years ended June 30, 
   2024   2023 
         
REVENUE          
Revenue  $-   $- 
           
OPERATING EXPENSES          
Administration expenses   1,253,797    1,499,885 
Occupancy expenses - related party   34,150    28,841 
Research and development   248,102    247,919 
TOTAL OPERATING EXPENSES   1,536,049    1,776,645 
           
LOSS FROM OPERATIONS   (1,536,049)   (1,776,645)
           
OTHER INCOME (EXPENSE)          
Interest expense   (665,841)   (532,821)
Interest income   60    36 
Derivative expense   (141,012)   - 
Change in fair value of derivative liabilities   316,537    (530,330)
Gain from settlement of accounts payable   -    17,499 
Gain on extinguishment of debt, net   54,565    25,969 
Foreign currency transaction gain   22,080    5,885 
TOTAL OTHER EXPENSE, NET   (413,611)   (1,013,762)
           
LOSS BEFORE TAXES   (1,949,660)   (2,790,407)
           
Tax benefit   129,132    129,841 
           
NET LOSS  $(1,820,528)  $(2,660,566)
           
Deemed Dividend   (192,960)   (466,273)
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(2,013,488)  $(3,126,839)
           
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS  $(0.02)  $(1.80)
           
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING   85,045,339    1,738,802 
           
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS  $(2,013,488)  $(3,126,839)
           
OTHER COMPREHENSIVE INCOME (LOSS)          
Unrealized foreign currency translation gain (loss)   (25,295)   60,327 
           
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)   (25,295)   60,327 
           
TOTAL COMPREHENSIVE LOSS  $(2,038,783)  $(3,066,512)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE YEARS ENDED JUNE 30, 2024 AND 2023

 

   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   Paid-in Capital  

Subscription

Receivable

   Accumulated Deficit   Comprehensive
Income
   Treasury Stock   Stockholders’
Deficit
 
   Preferred Stock           Common Stock               Accumulated         
   Series A   Series B   Common Stock   Issuable   Additional           Other       Total 
   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   No. of Shares   Value   Paid-in Capital  

Subscription

Receivable

   Accumulated Deficit   Comprehensive
Income
   Treasury Stock   Stockholders’
Deficit
 
                                                         
Balance at June 30, 2022   500,000   $5,000    1   $-    220,351   $220    19,598   $20   $57,364,690   $(23,758)  $(61,557,893)  $1,234,549   $(46,477)  $(3,023,649)
                                                                       
Issuance of common stock for cash   -    -    -    -    14,337    14    -    -    24,697    23,758    -    -    -    48,469 
                                                                       
Retirement of Series A Preferred Stock   (500,000)   (5,000)   -    -    -    -    -    -    5,000    -    -    -    -    - 
                                                                       
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest   -    -    -    -    5,061,180    5,061    807,230    807    1,381,855    -    -    -    -    1,387,723 
                                                                       
Issuance of common stock for services   -    -    -    -    79,412    79    608,423    608    138,260    -    -    -    -    138,947 
                                                                       
Issuance of common stock for exercise of Series B warrants   -    -    -    -    12    -    -    -    475,000    -    -    -    -    475,000 
                                                                       
Issuance of common stock for alternate cashless exercise of Series A warrants   -    -    -    -    559,999    560    206,000    206    (766)   -    -    -    -    - 
                                                                       
Issuance of common stock in connection with a note payable   -    -    -    -    75,000    75    -    -    37,425    -    -    -    -    37,500 
                                                                       
Issuance of common stock for issuable shares   -    -    -    -    19,598    20    (19,598)   (20)   -    -    -    -    -    - 
                                                                       
Reclassification of put premium upon debt conversion   -    -    -    -    -    -    -    -    411,111    -    -    -    -    411,111 
                                                                       
Warrant grant for settlement of accounts payable   -    -    -    -    -    -    -    -    5,551    -    -    -    -    5,551 
                                                                       
Stock based compensation in connection with stock warrant grant   -    -    -    -    -    -    -    -    2,408    -    -    -    -    2,408 
                                                                       
Foreign currency translation gain   -    -    -    -    -    -    -    -    -    -    -    60,327    -    60,327 
                                                                       
Deemed dividend upon alternate cashless exercise of warrants   -    -    -    -    -    -    -    -    466,273    -    (466,273)   -    -    - 
                                                                       
Fractional shares due to reverse split   -    -    -    -    1,361    2    -    -    (2)   -    -    -    -    - 
                                                                       
Net loss for the fiscal year ended June 30, 2023   -    -    -    -    -    -    -    -    -    -    (2,660,566)   -    -    (2,660,566)
                                                                       
Balance at June 30, 2023   -    -    1    -    6,031,250    6,031    1,621,653    1,621    60,311,502    -    (64,684,732)   1,294,876    (46,477)   (3,117,179)
                                                                       
Issuance of common stock for conversion of convertible debt and accrued interest   -    -    -    -    445,963,937    445,964    -    -    327,584    -    -    -    -    773,548 
                                                                       
Issuance of common stock for cash   -    -    -    -    18,913,648    18,914    -    -    4,143    -    -    -    -    23,057 
                                                                       
Issuance of common stock for alternate cashless exercise of warrants   -    -    -    -    6,272,000    6,272    -    -    (6,272)   -    -    -    -    -